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           Each year, Candida albicans causes ~700,000 cases of invasive life-threatening 
candidemia with a mortality rate of 40%. The opportunistic pathogen C. albicans is the fourth 
most common cause of nosocomial infections. While neutrophils are the first line of defence 
against invasive C. albicans, the yeast has developed several strategies to escape neutrophil 
killing effectively. The project aims to identify C. albicans genes that are important for the 
survival of neutrophil antifungal responses. These could then be exploited as future drug targets 
to stop C. albicans immune evasion. 
           A high-throughput fluorescence-based killing assay was established and used to screen 
384 conditional mutants from the GRACETM library, the largest publicly available C. albicans 
mutant library. Neutrophil-like cells, PLB-985, were used in the initial screen. Any mutants 
that were susceptible to PLB-985 killing were further validated with primary human 
neutrophils. Validated mutants were analysed in a series of functional assays to identify 
potential pathways and mechanisms involved in immune evasion.   
           25 out of 384 C. albicans mutants were found to be susceptible to PLB-985 killing. 
After four further validations with neutrophils, 5 mutants were found to be vulnerable to 
neutrophil killing. These mutants comprise brr2, taf7, noc3, tfb3 and smt3 with approximately 
38%, 44%, 27%, 28% and 29% reduction in cell viability relative to the C. albicans WT 
control, respectively. Functional assays further revealed that the five identified genes might 
play essential roles in C. albicans immune evasion. For example, the noc3 mutant appeared to 
be a weak inducer, and the tfb3 mutant appeared to be a strong inducer of reactive oxygen 
species and neutrophil extracellular traps production. Therefore, these genes may represent 
good therapeutic targets for candidemia.    
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CHAPTER 1: INTRODUCTION 
 
1.1 CANDIDA ALBICANS IS A MAJOR FUNGAL PATHOGEN 
OF HUMANS 
 
1.1.1 CANDIDA ALBICANS IN THE HEALTHY HOST  
 
Candida albicans is one of humans’ most common opportunistic fungi, affecting millions 
worldwide (Bongomin et al., 2017). It is a member of the human microbiota and a commensal 
of the skin, oral cavity, and gastrointestinal and genitourinary tracts in healthy individuals 
(Brown et al., 2012, Erdogan and Rao, 2015, Pappas et al., 2018). Like other members of the 
human microbiota, the C. albicans population is tightly regulated and kept under control by 
our immune system (Figure 1.1), particularly by the innate immune cells such as macrophages 
and neutrophils (Abbas et al., 2018, Gazendam et al., 2016, Qin et al., 2016, Wibawa, 2012). 
A weak immune system can lead to the overgrowth of C. albicans and provide this microbe 
with an opportunity to turn into a pathogenic fungus by allowing it to express its virulence 
factors to establish an infection. Therefore, immunocompromised individuals are particularly 
vulnerable to C. albicans infections, also known as candidiasis (Brown et al., 2012, Erdogan 






Figure 1.1: A healthy immune system controls C. albicans. C. albicans is a commensal 
member of the human microbiota. Its population is kept under control by host immune cells, 
such as neutrophils and macrophages. An impairment in immune function and an increase in 
C. albicans virulence factors can lead to candidiasis. [Adapted from (Abbas et al., 2018, Brown 
et al., 2012, Erdogan and Rao, 2015, Gazendam et al., 2016, Martins et al., 2014, Pappas et al., 
2018)]. Created with BioRender.com  
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1.1.2 C. ALBICANS IS THE 4TH MOST COMMON CAUSE OF 
NOSOCOMIAL BLOODSTREAM INFECTIONS 
 
Candidiasis is a broad-spectrum disease (Figure 1.2) commonly associated with C. albicans. 
It can affect different parts of our body, from superficial sites to deep systemic (invasive) 
infections (Martins et al., 2014, Pappas et al., 2018, Vazquez-Gonzalez et al., 2013). 
 
1.1.2.1 SUPERFICIAL CANDIDIASIS  
Superficial candidiasis is a localised infection that is limited to the skin surface (cutaneous 
candidiasis), mucous membrane (mucosal candidiasis) and genital area (Figure 1.2) (Martins 
et al., 2014, Vazquez-Gonzalez et al., 2013). Superficial candidiasis is a reasonably common 
infection. For example, 5-7% of babies were estimated to develop oral candidiasis, while 
around 75% of women were estimated to have at least one episode of vulvovaginal candidiasis 
in their lifetimes (Patil et al., 2015, Goncalves et al., 2016).  
 
Superficial candidiasis risk factors: 
One of the significant underlying risks of acquiring superficial candidiasis is having a 
compromised immune system. For example, people who are living with human 
immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) often suffer 
from oesophageal candidiasis (Anwar et al., 2012, de Repentigny et al., 2004). Similarly, 
oropharyngeal candidiasis is often seen and commonly associated with morbidity and mortality 
in cancer patients on immunotoxic therapies, such as cytotoxic chemotherapy and radiotherapy 
(Jayachandran et al., 2016, Maksymiuk et al., 1984). Interestingly, the use of oral 
contraceptives has been shown to associate with the risk of developing vulvovaginal 




Figure 1.2: Example of candidiasis clinical presentations. (a.) Oral thrush or mucosal 
candidiasis. (b.) Candidemia. Created with BioRender.com  
 
1.1.2.2 INVASIVE CANDIDIASIS  
Invasive candidiasis is the most severe form of C. albicans infection (Bongomin et al., 2017, 
Brown et al., 2012). There were estimated to be ~700,000 cases worldwide in 2017, where 
5,142 cases were reported in the UK in 2016 (Bongomin et al., 2017, Pegorie et al., 2016). 
Unlike superficial candidiasis that locally affects the mouth and throat or vaginal tract, invasive 
candidiasis can evade and spread to other parts of the body, such as the bloodstream, brain, 
heart and lungs (Brown et al., 2012, Kullberg and Arendrup, 2015).  
 
Candidemia, defined as the presence of Candida species in the bloodstream (Figure 1.2b 
and Figure 1.3), is the most common form of invasive candidiasis, with a more than 40% death 
rate (Bongomin et al., 2017, Kullberg and Arendrup, 2015). C. albicans is one of the fourth 
most common causes of nosocomial bloodstream infection, commonly observed in 
immunocompromised individuals, including critically ill patients, older people and premature 




Figure 1.3: Pathogenesis of Candidemia. (a.) C. albicans is a member of the gastrointestinal 
tract microbiota. (b.) When there are breaches in the gastrointestinal tract barriers, for example, 
anastomotic leakage after invasive laparostomy, C. albicans can disseminate and invade the 
bloodstream, resulting in candidemia. (c.) Similarly, medical devices, such as intravascular 
catheters, may carry C. albicans originating from the skin or gut, leading to colonisation and 
biofilm formation on the catheter. This biofilm formation of C. albicans can cause persistent 
candidemia. (d.) During candidemia, C. albicans in the bloodstream may spread to other 
organs, such as the heart, lungs, liver, spleen and bones. Immune system impairment, as well 
as having other risk factors, can promote these secondary deep-seated metastatic infections. 




Candidemia risk factors:  
Not having efficacious antifungal therapeutics, the incidence of nosocomial candidemia 
continues to rise over the past decades (Bongomin et al., 2017, Fridkin and Jarvis, 1996, 
Wisplinghoff et al., 2004). The increasing incidence of candidemia is thought to be due to the 
increase of risk factors (Figure 1.4) (Martins et al., 2014). 
 
Like superficial candidiasis, a compromised immune system is one of the main risk factors for 
acquiring candidemia (Kullberg and Arendrup, 2015, Martins et al., 2014, Yapar, 2014). For 
example, people who suffer from immunodeficiency conditions, such as CARD9 deficiency 
(mutations in a gene called caspase recruitment domain family member 9) and chronic 
granulomatous disease (CGD, an inherited disorder that results in phagocyte dysfunction) have 
a greater risk of having candidemia (Alves de Medeiros et al., 2016, Drewniak et al., 2013). 
Similarly, people who are taking immunosuppressive or immunotoxic therapies, such as those 
who suffer from autoimmune diseases, received transplantations and cancer patients, are also 
vulnerable to candidemia (Golecka et al., 2006, Li et al., 2017, Maksymiuk et al., 1984, 
Vaquero-Herrero et al., 2020, Yapar, 2014).  
 
The use of broad-spectrum antibiotics is another important risk factor of candidemia due to 
their ability to disturb the homeostasis of the human microbiota and promote C. albicans 
colonisation (Seelig, 1966, Shankar et al., 2015). A healthy host-microbiome helps to keep C. 
albicans numbers in control, in addition to a healthy immune system (Stefanaki, 2019). For 
example, studies showed that lactobacilli (Gram-positive bacteria), common members of the 
human microbiome, could inhibit the growth of C. albicans and its virulence factors, such as 
adherence ability, hyphae transformation and biofilm formation (Jang et al., 2019, Matsuda et 
al., 2018).  
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Invasive medical interventions (i.e., procedures that purposely invade or access the body, 
usually via incision or puncture), such as implanting cardiac devices or inserting catheters, can 
provide easier access for C. albicans to enter the bloodstream. At the same time, these devices 
also provide surfaces for C. albicans to form biofilms on (Kojic and Darouiche, 2004, Yapar 
et al., 2011). 
 
Diabetes mellitus, a chronic metabolic disorder, is another high-risk factor for obtaining 
candidemia (Bader et al., 2004, Calvet and Yoshikawa, 2001, Ostrosky-Zeichner et al., 2002). 
People with diabetes mellitus suffer from chronic hyperglycaemia, vascular remodelling and a 
dysfunctional immune system (such as impaired neutrophil functions) (Calvet and Yoshikawa, 
2001, Delamaire et al., 1997, Rodrigues et al., 2019). These are favourable conditions for C. 
albicans to thrive in. For example, high blood sugar levels provide a rich source of nutrients 
and energy for C. albicans metabolism, whereas vascular remodelling increases accessibility 
to the bloodstream (Bader et al., 2004, Rodrigues et al., 2019). Also, diabetic patients require 
regular blood glucose level checks and daily insulin injections, which are risk factors (Bader 
et al., 2004, Calvet and Yoshikawa, 2001, Delamaire et al., 1997, Rodrigues et al., 2019). 
 
Candidemia does not usually spread directly from person to person. However, patients with 
high-risk factors can acquire candidemia due to poor hygiene in healthcare settings (Pappas et 
al., 2016, Pfaller and Diekema, 2007). For example, many studies showed frequent Candida 
carriage on the hands of healthcare professionals, which may be a predisposing factor for 
nosocomial candidemia (Lupetti et al., 2002, Strausbaugh et al., 1994, Yildirim et al., 2007). 
Therefore, it is crucial to ensure a high standard of cleanliness and hygiene when interacting 
with patients or performing invasive procedures. To further prevent candidemia, high-risk 
 8 





Figure 1.4: Clinical interaction with candidemia: a summary diagram of the risk factors, 
prevention and control measures, diagnoses and treatments of candidemia caused by C. 
albicans [Adapted from (Kullberg and Arendrup, 2015, Martins et al., 2014, Pappas et al., 
2016)].  
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Candidemia clinical presentations: 
People who develop candidemia do not ordinarily present infection-specific symptoms and 
often already suffer from other medical conditions. This means their existing conditions’ 
symptoms can overshadow candidemia (Antinori et al., 2016, Pappas et al., 2018). However, 
fever and chills that do not improve after antibiotic treatment are the most common 
presentations of candidemia (Antinori et al., 2016). Candidemia can also cause septic shock, 
and thus patients may present with symptoms such as hypotension, tachycardia, and 
tachypnoea (Guzman et al., 2011, Kollef et al., 2012). Other symptoms can present if 
candidiasis spread to other parts of the body, such as the heart, bones and brain (Antinori et al., 
2016, Kullberg and Arendrup, 2015, Pappas et al., 2018). Therefore, it can be challenging to 
diagnose candidemia based on symptomatic presentation.  
 
Diagnosis of candidemia: 
The diagnostic gold standard for candidemia is blood cultures, which detect the presence of 
Candida in the bloodstream (Kullberg and Arendrup, 2015, Pappas et al., 2016). However, its 
overall sensitivity is only ~50%, with the limit of ≤1 colony-forming unit/mL and turnaround 
times ranging from 1 to ≥7 days (Berenguer et al., 1993, Clancy and Nguyen, 2013, Clancy 
and Nguyen, 2018, Pappas et al., 2016, Pfeiffer et al., 2011). However, many innovative 
culture-independent diagnostic tests are now entering into clinical practice as adjunctive tools. 
This includes Candida-antigen and -antibody detection (such as mannan, b-D-glucan and anti-
mannan IgG) with ~83% sensitivity and ~86% specificity, Polymerase Chain Reaction (PCR) 
test (T2Candida Panel) with at least 85% sensitivity and 98% specificity, and Mass 
Spectrometry (MALDI-TOF) with at least 90% sensitivity and specificity (Bader et al., 2011, 
Bille et al., 2012, Iriart et al., 2012, Kullberg and Arendrup, 2015, Mikulsa et al., 2010, 
Mylonakis et al., 2015, Wei et al., 2020). 
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Treatment of candidemia:  
Candidemia patients require a specific type and dose of antifungal treatments, which usually 
depend on the individual patient factors, such as age, immune status and other relevant 
comorbidities, including neutropenia and renal failure (Pappas et al., 2016). Echinocandins 
are often used as initial therapy for adult patients (Pappas et al., 2016). They inhibit b-(1,3)-D-
glucan synthase function, resulting in the weakening of the fungal cell wall, which can lead to 
osmotic lysis (Odds et al., 2003, Pappas et al., 2018). Antifungal azoles, such as Fluconazole, 
are often used as first-line agents for step down therapy (Pappas et al., 2016). They target 
human cytochrome P450-Erg11p, an enzyme that catalyses the removal of the 14a-methyl 
group of lanosterol. These agents inhibit 14a-demethylation of lanosterol in the ergosterol 
biosynthetic pathway. This causes the disturbance of fungal membrane permeability and 
synthesis (Odds et al., 2003, Pappas et al., 2018, Vanden Bossche et al., 1995). Polyene 
antifungal agents, such as Amphotericin B, are other first-line agents for step down treatment 
(Pappas et al., 2016). They directly bind to ergosterol and cause polar pore formation in the 
fungal membranes leading to osmotic lysis due to loss of ions, such as potassium and hydrogen 
ions (Ellis, 2002, Odds et al., 2003, Pappas et al., 2018). 
 
Antifungal resistance remains one of the biggest challenges when treating candidemia. Over 
time, C. albicans has developed effective strategies to avoid being killed by these antifungal 
treatments. For example, echinocandin-resistant C. albicans was found to have FKS1 
mutations, a gene associated with cell wall biogenesis (Balashov et al., 2006, Ben-Ami et al., 
2011, Desnos-Ollivier et al., 2008). Likewise, fluconazole-resistant C. albicans was found to 
overexpress ERG11, a gene associated with ergosterol production, and to overexpress MDR1, 
a gene that encodes drug efflux pumps (Dunkel et al., 2008, Flowers et al., 2012, Whaley et 
al., 2017). Therefore, there is an urgent need to develop novel antifungal therapeutics. 
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1.1.3 C. ALBICANS EXPRESSES A SUITE OF VIRULENCE 
FACTORS TO ESTABLISH AN INFECTION 
 
1.1.3.1 ADHERENCE 
The ability to adhere to the host cell surface is essential for C. albicans to colonise and establish 
infection successfully. Studies have shown a clear link between adherence ability and virulence 
of C. albicans (McCullough et al., 1996). For example, C. albicans strains that have increased 
ability to adhere to epithelial cells in vitro were demonstrated to have increased ability to cause 
infection in animal models (Ghannoum and Elteen, 1986, Rotrosen et al., 1986). It has been 
shown that C. albicans in the hyphal stage has a greater ability to adhere to host tissues than 
the yeast phase (Fu et al., 2002, Tsuchimori et al., 2000). C. albicans surface molecules called 
adhesins, mediate C. albicans binding to the host surface or its neighbouring cells (Cannon and 
Chaffin, 1999, Wibawa, 2016). Several genes have been proposed to be involved in adhesin 
production, such as ALS1 (encoding for Als1p, important for epithelial and endothelial cell 
adhesion) and HWP1 (encoding Hwp1p, important for epithelial cells) (Fu et al., 2002, Fu et 
al., 1998, Kumamoto and Vinces, 2005, Tsuchimori et al., 2000).  
 
1.1.3.2 DIMORPHISM  
C. albicans can exist in the unicellular yeast phase or multicellular and filamentous hyphal 
phase (Pappas et al., 2018, Wibawa, 2016). The transition (or dimorphism) between these two 
phases depends on several environmental conditions, such as temperature, pH and chemical 
constituents (Han et al., 2011, Kumamoto and Vinces, 2005, Molero et al., 1998, Wibawa, 
2016). Several genes are important in the morphogenesis of C. albicans, such as CPH1, EGF1, 
HGC1 and TUP1. Deletion of MAPK pathway members (CPH1 and EGF1) and the G1 cyclin 
related protein Hgc1 have been shown to halt filamentous growth, while deletion of TUP1 has 
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been shown to induce hyphal growth (Braun and Johnson, 1997, Braun and Johnson, 2000, 
Han et al., 2011, Lo et al., 1997, Zheng et al., 2004). The hyphal phase has also been suggested 
to be more virulent than the yeast phase (Lo et al., 1997, Tsuchimori et al., 2000). For example, 
a C. albicans egf1D/D cph1D/D mutant showed a significant reduction in pathogenicity in mice 
(Lo et al., 1997). Nevertheless, both morphologies are important in superficial and invasive C. 
albicans infections. Due to its ability to penetrate a deeper tissue layer, the hyphal form is 
considered to be important in tissue invasion, such as from the GI mucosal layer into vascular 
endothelium and reaching the bloodstream (Kullberg and Arendrup, 2015, Pappas et al., 2018, 
Wilson et al., 2016). The levels of adhesins and hydrolytic enzymes are also upregulated in the 
hyphal phase (Kumamoto and Vinces, 2005). Meanwhile, the yeast phase has been reported to 
play an important role in candidemia and C. albicans dissemination due to its budding ability 
and small size, for example, budding from hyphae to enter blood circulation, and ultimately 
spreading to various organs: bone, lungs, heart, liver and kidneys (Kullberg and Arendrup, 
2015, Pappas et al., 2018, Wibawa, 2016, Wilson et al., 2016).  
 
1.1.3.3 BIOFILM FORMATION 
A biofilm is a complex network or “structure of microbes consortium supported with an 
extracellular matrix which attaches to the surface” of the host (Wibawa, 2016). C. albicans 
often forms biofilm on medical devices, such as catheters, and host cell surfaces (Baillie and 
Douglas, 1999, Nobile and Johnson, 2015). Both yeast and hyphal phases are essential for 
biofilm formation (Nobile and Johnson, 2015, Wibawa, 2016). Biofilm serves as a reservoir 
for a source of infections (Ramage et al., 2012, Wibawa, 2012, Wibawa, 2016). Persistent 
candidemia often results from C. albicans yeasts that are constantly released from biofilm 
(Kullberg and Arendrup, 2015). Biofilm also provides a protective physical barrier for yeast 
cells and helps them escape from immune surveillance and protection against physical and 
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chemical environment stresses (Chandra et al., 2007, Ramage et al., 2012, Wibawa, 2012, 
Wibawa, 2016). 
 
1.1.3.4 PRODUCTION OF HYDROLYTIC ENZYMES 
C. albicans produces various hydrolytic enzymes to aid its pathogenic activities, including 
adherence to host surfaces, invasion of host tissues and evasion of the host’s antifungal 
responses. Secreted aspartyl proteinases, phospholipases and haemolysins are three keys 
hydrolytic enzymes of C. albicans (Wibawa, 2016).  
 
Secreted aspartyl proteinases (Saps) have been shown to support C. albicans in facilitating 
host invasion (Naglik et al., 2003). They are active in all candidiasis stages and cases 
(Staniszewska et al., 2012). Saps can degrade vital proteins that help maintain host structure, 
such as collagen and mucin (Fisher et al., 2011, Naglik et al., 2003). Their activity has been 
shown to link with C. albicans virulence (Fisher et al., 2011, Naglik et al., 2003, Schaller et 
al., 2000). C. albicans strains lacking Saps are less destructive in murine models, and they 
appeared to be less successful at colonising the host than those with functional Saps (Fisher et 
al., 2011, Hube et al., 1997).  
 
Phospholipases destabilise host membranes by hydrolysing glycerophospholipids, a major 
component of mammalian membranes (Fisher et al., 2011, Wilson et al., 2016). C. albicans 
isolates from candidemia patients appeared to have higher phospholipase activity than those 
obtained from oral cavities of healthy individuals, which reflected the virulence of these 
isolates (Ibrahim et al., 1995). Also, phospholipase-B knockout C. albicans mutants have 
shown to be less invasive than those with intact phospholipase-B (Leidich et al., 1998).   
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C. albicans produces haemolysins to induce haemolysis (rupturing of erythrocytes). This is 
important for C. albicans growth because erythrocytes contain haemoglobin, a protein that 
binds to iron. By causing haemolysis, C. albicans can extract its iron nutrient from 
haemoglobin (Almeida et al., 2009, Fisher et al., 2011, Wibawa, 2016).  
 
1.1.3.5 CANDIDALYSIN  
Candidalysin is a cytolytic peptide toxin secreted by C. albicans hyphae and was found to drive 
mucosal pathogenesis and modulate host immune responses by inducing epithelial activation 
and damage via MAPK signalling (Ho et al., 2019, Moyes et al., 2016, Swidergall et al., 2019a). 
Mutants that lack candidalysin could transition from yeast to hyphal phase with a similar 
invasion ability to the wild type control. However, they failed to induce epithelial damage and 
pro-inflammatory cytokine secretion (Moyes et al., 2016).   
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1.2 NEUTROPHILS ARE THE FIRST LINE OF DEFENCE 
AGAINST FUNGAL INVADERS  
 
1.2.1 NEUTROPHILS ARE MYELOID POLYMORPHONUCLEAR 
CELLS 
 
Neutrophils are a type of polymorphonuclear innate immune cell that act as a fast primary 
defence against fungal infections, such as candidiasis (Abbas et al., 2018, Gazendam et al., 
2016). They are the most abundant white blood cells (WBCs or leukocytes), representing about 
70% of all WBCs (Abbas et al., 2018, Amulic et al., 2012, Dancey et al., 1976, Gazendam et 
al., 2016). Neutrophils have one of the shortest lifespans of human cells: ~6-8 hours in 
circulation (Abbas et al., 2018, Amulic et al., 2012). However, their turnover is rapid, as around 
100 billion cells are released from the bone marrow per day (Abbas et al., 2018, Amulic et al., 
2012, Dancey et al., 1976, Scher et al., 2013, Summers et al., 2010). 
 
Neutrophils are derived from haematopoietic stem cells (HSCs) and develop in the bone 
marrow during a process called myelopoiesis under the instruction of various growth factors 
and cytokines, such as granulocyte colony-stimulating factor (G-CSF) (Figure 1.5). Pluripotent 
HSCs first differentiate into granulocyte precursor cells (myeloblasts). These precursor cells 
then undergoing sequential differentiation, and approximately after 14 days, mature 
neutrophils are released into the circulation. During neutrophil differentiation, neutrophils form 
three distinct granule subsets that contain many essential antimicrobial proteins that are 
important for fungal infections: primary [or azurophilic, containing, for example, antimicrobial 
defensins, myeloperoxidase (MPO), lysozyme and Cathepsin G], secondary [or specific, 
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containing lysozyme and lactoferrin, for example] and tertiary [or gelatinase, containing 
gelatinase] granules (Abbas et al., 2018, Amulic et al., 2012, Borregaard, 2010, Borregaard 
and Cowland, 1997, Scher et al., 2013). During differentiation, neutrophils also develop a 
lobulated nucleus composed of transcriptionally inactive chromatin (Abbas et al., 2018, Amulic 




Figure 1.5: Neutrophil development in the common myeloid pathway. G-CSF; granulocyte 
colony-stimulating factor, HSCs: haematopoietic stem cells, MPO: Myeloperoxidase, NE: 
neutrophil elastase, PR3: proteinase 3, PTX3: Pentraxin 3. [Adapted from (Abbas et al., 2018, 
Amulic et al., 2012, Amulic et al., 2017, Borregaard, 2010, Borregaard and Cowland, 1997, 






1.2.2 NEUTROPHILS ARE THE FIRST CELLS TO MIGRATE TO 
THE SITE OF AN INFECTION 
 
During infection, neutrophils are the first immune cells to be recruited from circulation to the 
site of an infection, for example, in response to chemokines produced by tissue-resident 
macrophages. Although mononuclear macrophages are some of the first cells to interact with 
pathogens, they are nowhere near as potent as neutrophils, which can utilise several 
antimicrobial methods to kill pathogens, such as C. albicans (Abbas et al., 2018, Ermert et al., 
2013, Rudkin et al., 2013, Vonk et al., 2002). The importance of neutrophil functions in 
candidiasis can be demonstrated by the increasing risk of candidemia in neutropenic patients 
(Pappas et al., 2016, Pfaller and Diekema, 2007). 
 
1.2.2.1 NEUTROPHIL RECRUITMENT 
During candidiasis (Figure 1.6), C. albicans induces tissue damage and inflammation, for 
example, by candidalysin, which results in the production of various pro-inflammatory 
cytokines, such as tumour necrosis factor (TNF)-a, Interleukin (IL)-1b, IL-6 and IL-17, as well 
as the production of G-CSF (Abbas et al., 2018, Amulic et al., 2012, Borregaard, 2010, Cheng 
et al., 2012, Moyes et al., 2016, Swidergall et al., 2019a). These cytokines cause the 
upregulation of endothelial adhesion molecules on the vascular endothelium surface, causing 
neutrophil tethering to vascular endothelium. Neutrophils then engage in transendothelial-
migration through tight junctions via a process called diapedesis, moving to the site of infection 
down concentration gradients of either host-derived chemotactic cytokines, such as IL-8, or 
pathogen-derived chemoattractants, such as C. albicans b-1,3-D-glucans (Abbas et al., 2018, 





Figure 1.6: Neutrophil recruitment to C. albicans infection site. (1.) C. albicans causes 
tissue inflammation, resulting in cytokine release and upregulation of endothelial adhesion 
molecules. (2.) Adhesion stage: circulating neutrophil binds its selectin receptor to endothelial 
selectins. (3.) Rolling stage: more binding of selectins to its receptor. (4.) Tethering stage: the 
binding of neutrophil integrins to intracellular adhesion molecules (ICAMs) results in firm 
adhesion. (5.) Diapedesis. (a.) Phagocytosis. (b.) Degranulation. (c.) NETosis. (d.) 
Cytokine/Chemokine production. [Adapted from (Abbas et al., 2018, Amulic et al., 2012, 
Borregaard, 2010)]. Created with BioRender.com  
 
Patients with autosomal recessive leukocyte adhesion deficiency (LAD) syndromes have 
neutrophils that cannot exit blood circulation due to mutations in various receptors required for 
transmigration and thus cannot migrate to the site of infection (Etzioni, 1996, Etzioni, 2010, 
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von Andrian et al., 1993). Patients with LAD syndromes are often infected by C. albicans and 
die from fungal septicaemia (Movahedi et al., 2007, Parvaneh et al., 2010). To emphasise the 
importance of neutrophil recruitment, mouse studies also showed that neutrophils lacking 
integrins and mice lacking ICAMs have impaired migration and impaired ability to kill C. 
albicans (Davis et al., 1996, Soloviev et al., 2011). 
 
1.2.2.2 PATHOGEN RECOGNITION RECEPTORS 
The cell wall of C. albicans is essential for maintaining viability. C. albicans is composed of 
components (pathogen-associated molecular patterns or PAMPs) that are generally not present 
in our body, such as b-glucans, mannan and chitin (Gazendam et al., 2016, Netea et al., 2008). 
Neutrophils express various types of pattern recognition receptors (PRRs) to recognise several 
kinds of C. albicans PAMPs (Figure 1.7) (Gazendam et al., 2016).  
 
One of the main neutrophil PRRs are Toll-like receptors (TLRs). TLRs consist of two main 
domains: an extracellular domain that is responsible for C. albicans structure recognition and 
a cytoplasmic domain that is responsible for inducing intracellular response (Abbas et al., 2018, 
Gow et al., 2012). Membrane-bound TLRs, such as TLR-2 and TLR-4, recognise 
phospholipomannans and O-linked mannans, respectively. Intracellular TLRs, such as TLR-9, 
recognise C. albicans DNA (Gow et al., 2012, Netea et al., 2008, Netea et al., 2002). Mice 
deficient in MyD88, the common downstream adaptor molecule for various TLRs, were 
reported to be susceptible to invasive candidiasis, thus demonstrating the significant global role 
of TLRs in defence against C. albicans infection (Marr et al., 2003, Netea et al., 2008, Villamón 
et al., 2004a). Further studies also reported that TLR-2 deficient mice are susceptible to 




Figure 1.7: The interaction between neutrophil pattern recognition receptors and C. 
albicans pathogen-associated molecular patterns. TLRs initiate their intracellular cascade 
via MyD88/IRAK/TRAF pathway to activate NF-kB transcription upon binding to their 
ligands. TLR-4, a special member of TLRs, can also activate IFN-1 transcription via 
TRIF/IRF3 pathway. Tyrosine kinase domains of CR3, dectin-1 and dectin2-FcgR get 
phosphorylated upon binding to their ligands, which in turn initiates NF-kB transcription via 
the CARD9 pathway. NF-kB and IFN-1 signalling are essential in inflammatory and antifungal 
responses. When EphA2 binds to its ligand, it initiates the MEK/ERK pathway, which in turn 
initiates phospho-priming the NADPH oxidase complex component. [Adapted from (Cheng et 
al., 2012, Gazendam et al., 2016, Gow et al., 2012, Netea et al., 2008, Pappas et al., 2018, 
Swidergall et al., 2019b)]. Created with BioRender.com  
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C-type lectin receptors (CLRs) are the most crucial type of receptors that neutrophils use to 
recognise C. albicans polysaccharide structures. Two main CLRs expressed on human 
neutrophils are dectin-1 (encoded by human CLEC7A) that recognises b-glucans (such as b-
1,3-and b-1,6-glucans), and dectin-2 (encoded by human CLEC6A) that binds to a-mannans 
(Gazendam et al., 2016, Gow et al., 2012). The binding of dectin-1 or dectin-2 to their ligands 
initiates neutrophil intracellular signalling mediated through various pathways, such as Syk-
CARD9 and NF-kB, to produce antifungal responses (Brown and Gordon, 2001, Gazendam et 
al., 2016, Gow et al., 2012). The vital role of dectin-1 and dectin-2 in anti-C. albicans defence 
can be demonstrated by in vivo studies, whereby dectin-1 and dectin-2 knockout mice have an 
increased susceptibility to systemic candidiasis (Brown and Gordon, 2001, Gazendam et al., 
2016, Saijo et al., 2010, Taylor et al., 2007). Patients with CARD9 deficiency are vulnerable 
to C. albicans infections, and neutrophils isolated from these patients were defective in C. 
albicans killing (Drewniak et al., 2013, Drummond et al., 2019, Glocker et al., 2009).  
    
There are many other PRRs that neutrophils use to recognise C. albicans, such as complement 
receptor (CR)-3 integrins that recognise b-glucans and Fc-gamma receptors (FcgRs) that 
bind to antibodies of opsonised C. albicans (Gazendam et al., 2016). All of these PRRs 





1.2.3 NEUTROPHIL ANTIFUNGAL RESPONSES  
 
Neutrophils become activated upon the binding of their PRRs to C. albicans PAMPs. They 
then utilise many antifungal mechanisms to counteract C. albicans, including cytokine 
production, phagocytosis, degranulation and neutrophil extracellular traps (NETs) (Amulic et 
al., 2012, Gazendam et al., 2016).  
 
1.2.3.1 CYTOKINE PRODUCTION 
Cytokine production is an indirect strategy of neutrophils to suppress C. albicans. When 
neutrophils encounter C. albicans, they release various cytokines and chemokines to attract 
and crosstalk with other immune cells (Amulic et al., 2012, Niemiec et al., 2017, Scapani et 
al., 2000). A transcriptional study showed an increase in cytokine genes of neutrophils in 
response to C. albicans, such as those encoding for macrophage inflammatory protein (MIP)-
1b, IL-1b, IL-8, macrophage-colony stimulating factor (M-CSF) and TNF-a (Niemiec et al., 
2017). IL-8 is responsible for recruiting other neutrophils, while IL-1b and TNF-a induce other 
local cells to produce neutrophil chemoattractants (Amulic et al., 2012, Scapani et al., 2000). 
Other cytokines produced by neutrophils, such as MIP-1a and IL-12, are important for 
recruitment of monocytes, macrophages, natural killer (NK) cells and dendritic cells, and 
induction of Th1 lymphocyte differentiation and responses (Abbas et al., 2018, Amulic et al., 
2012, Leonard and Yoshima, 1990, Tateda et al., 2001).  
 
1.2.3.2 PHAGOCYTOSIS 
Phagocytosis is a key process in the neutrophil antifungal response against C. albicans 
(Gazendam et al., 2016). Phagocytosis is initiated when neutrophil PRRs bind to C. albicans 
PAMPs or opsonised C. albicans (Amulic et al., 2012, Gazendam et al., 2016). First, the 
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neutrophil engulfs or phagocytoses C. albicans by surrounding its pseudopodium around the 
yeast cell, forming a phagosome. The phagosome then fuses with neutrophil preformed 
granules, containing several enzymes and antimicrobial proteins that mediate C. albicans 
killing (Amulic et al., 2012, Segal, 2005). Ultimately, C. albicans gets digested and killed by 
neutrophils by enzymatic killing and toxic reactive oxygen species. Once neutrophils have 
performed their antifungal function, they die via apoptosis and get cleared by macrophages 
(Amulic et al., 2012, Abbas et al., 2018).  
 
1.2.3.3 DEGRANULATION 
Degranulation is a process where a neutrophil releases its antimicrobial factors and enzymes 
and other molecules from its “granules” or secretory vesicles (Lacy, 2006). Neutrophil granules 
can either fuse into the phagosome to kill pathogens or fuse with the plasma membrane and 
degranulate extracellularly via a process called exocytosis (Amulic et al., 2012). Familial 
hemophagocytic lymphohistiocytosis type 5 (FHL-5) is an autosomal recessive disorder caused 
by mutations in STXBP2, a gene encoding for syntaxin binding protein Munc18-2 required for 
the fusion of granules to the plasma or phagosomal membrane (zur Stadt et al., 2009). FHL-5 
patients are deficient in Munc18-2 proteins, and their neutrophils were found to be defective at 
killing C. albicans, thus demonstrating the importance of neutrophil degranulation (Gazendam 
et al., 2016).  
 
1.2.3.4 OXIDATIVE RESPIRATORY BURST 
Oxidative respiratory burst is one of the main antifungal mechanisms of neutrophils (Figure 
1.8). This process is assisted by the fusion of specific granules to the plasma membrane or 
phagosome. Specific granules contain flavocytochrome b558, a catalytic core that is vital for 
NADPH oxidase (NOX2) complex activation and reactive oxygen species (ROS) production, 
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such as superoxide anions (O2.-) and hydrogen peroxide (H2O2) (Amulic et al., 2012, Segal, 
2005). Similarly, when azurophilic granules fuse with plasma or phagosomal membrane, they 
release MPO - an enzyme that converts hydrogen peroxide into other reactive species, such as 
hypochlorous acid (HOCL) (Amulic et al., 2012, Jamieson et al., 1996, Segal, 2005). ROS are 
highly unstable molecules that can react with and modify various organic substances, such as 
proteins and DNA of C. albicans, leading to candidal cell death (Amulic et al., 2012, Jamieson 
et al., 1996, Kobayashi et al., 2002, Segal, 2005). A defect in any components of NOX2 often 
result in the loss of ROS production and thus impaired neutrophil antifungal responses (Amulic 
et al., 2012, Gazendam et al., 2016). For example, patients with chronic granulomatous disease, 
an immunodeficiency caused by mutations in NOX2 complex genes, often suffer from 
recurrent C. albicans infections (Cohen et al., 1981, Gazendam et al., 2016, Song et al., 2011).  
 
 
Figure 1.8: NADPH oxidase complex and reactive oxygen species production. Assembly 
and activation of NOX2 complex (aided by flavocytochrome b558, not shown) cause the 
reduction of oxygen molecules into superoxide anions (O2.-). An enzyme, superoxide dismutase 
(SOD), further converts O2.- into hydrogen peroxide (H2O2). Myeloperoxidase (MPO) from 
azurophilic granules converts H2O2 into hypochlorous acid (HOCL). [Adapted from (Amulic 
et al., 2012, Gazendam et al., 2016, Nguyen et al., 2017, Segal, 2005)]. Created with 
BioRender.com  
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In addition to NOX2 components, neutrophil granules contain other enzymes and antimicrobial 
proteins, which are important in C. albicans killing. For example, lysozyme or muramidase 
(stored in both azurophilic and specific granules) is vital in breaking down C. albicans cell wall 
components (Amulic et al., 2012, Marquis et al., 1991, Marquis et al., 1982). It was also found 
to degrade Candida Saps and thus inhibited the growth of C. albicans (Wu et al., 1999). 
Cathepsin G, neutrophil elastase and proteinase 3, from azurophilic granules, act similarly by 
cleaving fungal proteins via proteolysis (Amulic et al., 2012, Faurschou and Borregaard, 2003, 
Segal, 2005). Proteinase 3 was found to cleave the C-terminus of hCAP-18 (human 
cathelicidin) to release LL-37 (Sørensen et al., 2001). LL-37 is an antimicrobial peptide that 
has been shown to enhance the b-1,3-exoglucanase activity of Xog1p, which reduces C. 
albicans cell wall integrity (Chang et al., 2012). Azurophilic granules also contain 
antimicrobial defensins, such as a-and b-defensins (Amulic et al., 2012). Human neutrophil a-
defensin-1 was found to kill C. albicans by inducing ATP efflux and depleting intracellular 
ATP levels (Edgerton et al., 2000). Human b-defensin-3 was found to reduce C. albicans 
adherence ability and its viability by disrupting fungal cell wall formation (Chang et al., 2012, 
Feng et al., 2005).  
 
Similar to azurophilic granules, specific granules also contain antimicrobial proteins that are 
involved in C. albicans killing. For example, lactoferrin was shown to inhibit the growth of C. 
albicans by binding to its iron nutrient (Bellamy et al., 1993, Kirkpatrick et al., 1971). Another 
example is PTX3, a soluble PRR that can enhance C. albicans clearance by increasing 
phagocytotic uptake through the interaction with complement factors and bringing NET 




1.2.3.5 NEUTROPHIL EXTRACELLULAR TRAPS 
The production of neutrophil extracellular traps (NETs) is another crucial microbe killing 
mechanism. NETs are characterised by large, extracellular, web-like structures of DNA, 
histones and granule antimicrobial proteins (Figure 1.9). They also contain molecules that 
mediate and activate immune responses, such as alarmins (Amulic and Sollberger, 2019, 
Branzk et al., 2014, Papayannopoulos, 2018). When neutrophils come across pathogens that 
are too large to phagocytose, they undergo a unique form of death, called NETosis, whereby 
NETs are released and entrap pathogens (Branzk et al., 2014). This is particularly important as 
an antifungal response against C. albicans, a species that can switch its phenotype from a small 
yeast cell to a large filamentous hypha (Pappas et al., 2018). Studies have demonstrated that 
neutrophils release NETs as an antifungal response to C. albicans, with a predominant effect 
on those in hyphal form (Branzk et al., 2014, Urban et al., 2006). Also, the neutrophil dectin-2 
receptor was found to mediate NETosis upon binding C. albicans (Miura et al., 2019, 
Papayannopoulos, 2018, Wu et al., 2019). Furthermore, a study has revealed that calprotectin, 
a component of NETs, plays a vital role in the clearance of C. albicans infections (Urban et al., 
2009). Calprotectin is a cytosolic protein complex that interferes with C. albicans growth and 
survival by chelating their essential metal ion nutrients, such as Zn2+ and Cu2+ (Besold et al., 






Figure 1.9: Neutrophil extracellular trap (NET) mechanisms. The generation of reactive 
oxygen species (ROS) from the NADPH oxidase complex causes neutrophil elastase (NE) to 
be released from the azurophilic granules. NE then translocates into the nucleus and cleaves 
the histones, causing chromosome decondensation. Ultimately, the chromatin expands and fills 
the cells, “bursting” NETs contents into the extracellular space. [Adapted from (Amulic and 




1.3 CANDIDA ALBICANS EVOLVED EFFECTIVE 
STRATEGIES TO ESCAPE AND EVADE NEUTROPHIL 
ANTIFUNGAL RESPONSES 
 
1.3.1 C. ALBICANS UTILISES ITS VIRULENCE FACTORS TO 
ESCAPE NEUTROPHIL KILLING 
 
To survive and reproduce, C. albicans has developed novel strategies to escape from being 
killed by neutrophils. Its virulence factors can help it to achieve this by interfering with 
neutrophil antifungal responses. These strategies include the following: 
 
1.3.1.1 DIMORPHISM 
Each C. albicans morphology has its own advantage in terms of escape from neutrophil 
antifungal responses. For example, the hyphal phase was found to be resistant to phagocytosis, 
while the yeast phase was found to induce less pro-inflammatory cytokines and neutrophil 
chemoattractants from epithelial cells (Jayatilake et al., 2007, Moyes et al., 2010, Naglik et al., 
2011, Salvatori et al., 2018). A mouse study also showed that engulfed C. albicans yeast could 
escape from the neutrophil phagosome by switching to hyphal growth and causing the cell to 
rupture (Ermert et al., 2013). Therefore, the ability to undergo yeast-hyphae morphogenesis is 
vital in helping C. albicans to escape neutrophil killing.  
 
1.3.1.2 BIOFILM FORMATION 
Biofilm provides a protective physical barrier for yeast cells and helps them escape from 
neutrophil surveillance (Wibawa, 2012). Biofilm formation of C. albicans has been shown to 
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reduce neutrophil-mediated killing by preventing phagocytosis, ROS and NETs release 
(Johnson et al., 2016, Kernien et al., 2020, Lohse et al., 2018, Xie et al., 2012). Therefore, the 
biofilm formation ability of C. albicans serves as a crucial strategy in its neutrophil resistance.  
 
1.3.1.3 PRODUCTION OF HYDROLYTIC ENZYMES 
Hydrolytic enzymes, such as Saps, were found to have the ability to degrade C5a complement 
(an important molecule for neutrophil recruitment and activation), as well as other complement 
proteins that prime C. albicans for neutrophil recognition and killing (Abbas et al., 2018, 
Gazendam et al., 2016, Singh et al., 2020). They were also found to degrade IL-37. IL-37 is 
important for ROS and IL-8 production, and it has the ability to prolong neutrophil lifespan 
(Rapala-Kozik et al., 2015). It is unclear how phospholipases and haemolysins interfere with 
neutrophil killing, but evidence suggested that they are important in C. albicans survival 
(Fisher et al., 2011, Wibawa, 2016). 
 
1.3.1.4 ANTIOXIDANT PROTEINS 
C. albicans contains superoxide dismutases (Sods), enzymes that detoxify ROS from 
neutrophils. Sods eliminate superoxide anions by catalysing the reaction that converts O2.- into 
a less reactive H2O2 species (Martchenko et al., 2004, Poulain, 2015). There are six Sod 
proteins. Some of them were associated with the fungal cell wall, such as Sod4, Sod5 and Sod6, 
that provide a quicker response to neutrophil antifungal responses than those in the cytoplasm 
(Fradin et al., 2005, Niemiec et al., 2017, Poulain, 2015). SOD genes were also found to be 
upregulated in yeast cells when interacting with neutrophils (Niemiec et al., 2017). The 
importance of Sod proteins can be further demonstrated by the sensitivity and susceptibility of 
mutants lacking Sod enzymes, such as Sod5, to neutrophil killing (Fradin et al., 2005).   
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1.3.1.5 ALTERING CELLULAR METABOLISM  
C. albicans can alter its metabolism as part of a stress response when encountering neutrophils. 
C. albicans was found to upregulate the glyoxylate cycle upon phagocytosis (Barelle et al., 
2006, Miramon et al., 2012). For example, C. albicans was found to upregulate ICL1 (encodes 
for isocitrate) and MLS1 (encodes for malate synthase) which are vital in the activation of the 
glyoxylate cycle (Barelle et al., 2006, Lorenz and Fink, 2001). C. albicans lacking ICL1 was 
found to be more vulnerable to neutrophil killing (Miramon et al., 2012). This adaptation of C. 
albicans is crucial for its survival in an environment where nutrients and oxygen supplies are 
restricted, such as in the phagosome (Barelle et al., 2006).  
 
1.3.1.6 INDUCTION OF STRESS RESPONSE PATHWAYS 
C. albicans was found to activate MAPK pathways, such as Hog1, Cek1 and Ras1-GTPase, to 
resist neutrophil defences (Alonso-Monge et al., 2003, Csank et al., 1998, Ernst and Pla, 2011, 
Hollomon et al., 2016, Miramon et al., 2012, Salvatori et al., 2018). The Hog1 pathway is 
crucial in C. albicans resistance to osmotic and oxidative stresses, while the Cek1 pathway is 
vital for C. albicans cell wall biogenesis and morphogenesis (Alonso-Monge et al., 2003, 
Csank et al., 1998, Ernst and Pla, 2011, Miramon et al., 2012). Similarly, the Ras1-GTPase 
pathway is also important in C. albicans morphogenesis and its responses against pH stress 
(Hollomon et al., 2016, Salvatori et al., 2018). Hog1 or Cek1 deletion mutants were shown to 
be more susceptible to neutrophil killing, while deletion of Ras1 was shown to have an opposite 
effect (Miramon et al., 2012, Salvatori et al., 2018).   
 
There are many more mechanisms that C. albicans utilises to counteract neutrophil antifungal 
responses. There will also likely be more C. albicans genes to be involved in these anti-
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neutrophil-mediated killing responses. By identifying these novel genes, it could be possible 





1.4 AIMS AND OBJECTIVES 
 
This research project aimed to identify C. albicans genetic factors that are important for the 
survival of neutrophil antifungal responses by screening the GRACETM mutant library.  
 
The main research objectives were:  
1. To optimise a high throughput chemiluminescence-based killing assay using 
alamarBlueTM and Calcofluor White reagents 
2. To establish a suitable multiplicity of infection (MOI) of C. albicans for the killing assay 
3. To establish PLB-985 cells (neutrophil-like cells) as a model for C. albicans killing assay 
4. To identify C. albicans mutants from the GRACETM library that are susceptible to PLB-
985 killing 
5. To validate C. albicans mutants from the GRACETM library that are susceptible to PLB-
985 killing with neutrophils 
6. To characterise C. albicans mutants (that are susceptible to neutrophils), using the 
following assays: 
- Ability to form somatic hyphae 
- Susceptibility to hydrogen peroxide 
- Susceptibility to cell wall stressors 
- Ability to induce neutrophil ROS  
- Ability to induce NETs   
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 MATERIALS   
 
2.1.1 CANDIDA ALBICANS STRAINS USED IN THIS STUDY 
Strains Source Reference 
CaSS1, Wild-type (WT) - GRACETM 
library background strain 
Merck & Co.  
 
(Roemer et al., 2003) 
GRACETM strain library  Merck & Co. (Roemer et al., 2003) 
CAI4  Bernhard Hube (Fradin et al., 2005) 
CAI4 - efg1Δ/Δ cph1Δ/Δ  Bernhard Hube (Wartenberg et al., 2014) 
SN95 Leah Cowen (Noble and Johnson, 2005) 
SN95 - hog1Δ/Δ Carolyn Williamson Diezmann lab archive 
SN95 - tup1Δ/Δ Michelle Leach Diezmann lab archive 
SN95 - mkk2Δ/Δ Carolyn Williamson Diezmann lab archive 
SN95 - pkc1Δ/Δ Carolyn Williamson Diezmann lab archive 
 
2.1.2 EUKARYOTIC CELLS USED IN THIS STUDY 
Primary human neutrophils Extracted from healthy donor blood  





2.1.3 C. ALBICANS CULTURE MEDIA & ADDITIVES  
D-Glucose (Anhydrous) Melford Biolaboratories Limited  
Doxycycline hydrochloride (as hyclate) Duchefa Biochemie B.V. 
Peptone  Sigma-Aldrich 
Yeast extract (YE) Sigma-Aldrich 
 
2.1.4 EUKARYOTIC CELL CULTURE & DIFFERENTIATION 
MEDIA AND ADDITIVES  
Clear RPMI-1640 medium (without Q, 
without phenol red) 
Gibco, Thermo Fisher Scientific 
Foetal bovine serum (FBS/FCS) Gibco, Thermo Fisher Scientific 
L-Glutamine (Q) Gibco, Thermo Fisher Scientific 
N, N-Dimethylformamide (DMF) Sigma-Aldrich  
Nutridoma-CS  Roche, Sigma-Aldrich  
Penicillin/Streptomycin/Glutamine (P/S/Q) Gibco, Thermo Fisher Scientific 
Red RPMI-1640 medium (without Q, with 
phenol red) 
Gibco, Thermo Fisher Scientific 
 
2.1.5 PLB-985 & PRIMARY HUMAN NEUTROPHIL ISOLATION  
EasySepTM Direct Human Neutrophil 
Isolation Cocktail 
StemcellTM Technologies   
EasySepTM Direct RapidSpheresTM 50300 StemcellTM Technologies   
EasySepTM Human Neutrophil Isolation Kit StemcellTM Technologies 
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Ethylenediaminetetraacetic acid (EDTA) Made by media kitchen from the University 
of Bristol 
Histopaque 1077 Sigma-Aldrich  
Histopaque 1119 Sigma-Aldrich 
Human Serum Albumin (HSA) Seqens 
PercollTM  GE Healthcare  
Phosphate-buffered saline (PBS), pH7.4 Gibco, Thermo Fisher Scientific 
 
2.1.6 C. ALBICANS – NEUTROPHIL KILLING ASSAY 
alamarBlueTM Cell Viability Reagent   Thermo Fisher Scientific 
Calcofluor White Stain 18909 (CFW) Sigma-Aldrich 
Clear RPMI-1640 medium (without Q, 
without phenol red) 
Gibco, Thermo Fisher Scientific 
Doxycycline hydrochloride (as hyclate) Duchefa Biochemie B.V. 
Human pooled plasma serum Extracted from healthy donor blood 
Paraformaldehyde (PFA) 4% in PBS VWR 
PBS tablets Oxoid 
Penicillin-Streptomycin-Glutamine (P/S/Q) Gibco, Thermo Fisher Scientific 
Triton X-100  Thermo Fisher Scientific  
 
2.1.7 C. ALBICANS SERUM-INDUCED FILAMENTATION ASSAY 
FBS Gibco, Thermo Fisher Scientific 
PBS tablets Oxoid 
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2.1.8 C. ALBICANS OXIDATIVE STRESS ASSAY 
Agar  Sigma-Aldrich  
D-Glucose (Anhydrous) Melford Biolaboratories Limited  
Hydrogen peroxide (H2O2) Sigma-Aldrich 
PBS tablets Oxoid 
Peptone  Sigma-Aldrich 
Yeast extract (YE) Sigma-Aldrich 
 
2.1.9 C. ALBICANS CELL WALL STRESS ASSAY 
Agar  Sigma-Aldrich  
Calcofluor White Stain 18909 (CFW) Sigma-Aldrich 
Congo Red  Sigma-Aldrich 
D-Glucose (Anhydrous) Melford Biolaboratories Limited  
M 2-(N-morpholine)-ethane sulfonic acid-
sodium hydroxide (MES-NaOH) pH 6.0 
Sigma-Aldrich 
Peptone  Sigma-Aldrich 
YE Sigma-Aldrich 
 
2.1.10 OXIDATIVE BURST ASSAY  
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Gibco, Thermo Fisher Scientific 
Hank’s Balanced Salt Solution (HBSS) (with 
Calcium (Ca2+) and Magnesium (Mg2+) ions) 
Lonza 
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Horseradish peroxidase (HRP) Sigma-Aldrich  
Luminol Sigma-Aldrich 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich  
 
2.1.11 NETOSIS ASSAY  
Clear RPMI-1640 medium (without Q, 
without phenol red) 
Gibco, Thermo Fisher Scientific 
Doxycycline hydrochloride (as hyclate) Duchefa Biochemie B.V. 
HEPES Gibco, Thermo Fisher Scientific 
HSA Lonza 
Human pooled plasma serum Extracted from healthy donor blood 
SYTOTM Green Thermo Fisher Scientific 





2.2 METHODS  
 
2.2.1 MULTIPLICITY OF INFECTION (MOI) EQUATIONS  
 
2.2.1.1 MOI EQUATION OF OD600 USING EPPENDORF BIOSPECTROMETER®  
            BASIC 
*OD600 of 1 = 2 x107 cell/mL 
 
2.2.1.2 MOI EQUATION OF OD595 USING MULTISKANTM FC MICROPLATE  
            PHOTOMETER (THERMO FISHER SCIENTIFIC) 
 
*OD595 of 1 = 1 x107 cell/mL 
 
*The optical density (OD) of C. albicans was measured at a wavelength of 595 or 600 nm to 
estimate the concentration of C. albicans cells in suspension. These equations were previously 
established by the Diezmann laboratory. They derived from the standard curve of OD595/600 
against colony forming units (CFU)/mL. 
 
2.2.2 C. ALBICANS CELL CULTURE  
 
2.2.2.1 CULTURING OF C. ALBICANS IN CULTURE TUBES  
Overnight: Wild-type (WT) strain or GRACETM mutants were inoculated into culture tubes 
with 10 mL of YPD (2% D-glucose, 2% peptone, 1% YE) media (with 0.05 µg/mL of 
doxycycline**) and incubated overnight for 17 hours at 30 °C and 200 rpm.    
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Subculture: Each overnight culture was diluted with YPD media (with 0.05 µg/mL of 
doxycycline) accordingly to get OD600 of 1. 50 mL of each diluted culture was subcultured for 
3 hours at 30 °C and 200 rpm.   
 
**The GRACETM mutants were created by deleting one allele of a target gene and placing the 
other copy under the control of a Tetracycline (Tet) repressive promoter. Doxycycline, a Tet 
analogue, is added to the culture to inhibit target gene expression completely (Roemer et al., 
2003). 
 
2.2.2.2 OPTIMISATION: CULTURING OF C. ALBICANS IN A 96-WELL PLATE  
Overnight: WT strain was inoculated into a clear flat-bottom 96-well plate (Corning 
Incorporated) filled with 100 µL of YPD media, using a 96 long-pin RePad (Singer). The plate 
was sealed with breathable rayon film (VWR) and incubated overnight for 17 hours at 30 °C 
and 800 rpm.  
 
Subculture: The overnight WT cultures were diluted with YPD media, using the following 
dilution factors: 1, ½, ¼. A 96 floating E-Clip style (VP408F6S.5, V & P Scientific) was used 
to transfer the diluted cultures into a clear flat-bottom 96-well plate (Corning incorporated) 
filled with 100 µL of YPD media. The plate was sealed with breathable rayon film (VWR) and 
incubated for 3 hours at 30 °C and 800 rpm. After the incubation, the plate was centrifuged at 
1000 x g for 3 minutes. The supernatant was removed, and cells were resuspended in 100 µL 
of 1X (w/v) PBS.  
 
The plate OD595 values were used to determine the required volume of C. albicans suspension 
to obtain 150,000 cells/well for the GRACETM library screen.  
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2.2.2.3 CULTURING OF THE GRACETM LIBRARY PLATES 
Overnight: WT strain and GRACETM mutants were inoculated into clear flat-bottom 96-well 
plates (Corning incorporated) filled with 100 µL of YPD media (with 0.05 µg/mL of 
doxycycline), using a 96 long-pin RePad (Singer). These plates were sealed with breathable 
rayon film (VWR) and incubated overnight for 17 hours at 30 °C and 800 rpm.  
 
Subculture: A 96 floating E-Clip style (VP408F6S.5, V & P Scientific) was used to transfer 
WT strain and GRACETM mutants’ overnight cultures into clear flat-bottom 96-well plates 
(Corning incorporated) filled with 100 µL of YPD media (with 0.05 µg/mL of doxycycline). 
These plates were sealed with breathable rayon film (VWR) and incubated for 3 hours at 30 
°C and 800 rpm. After the incubation, the plates were centrifuged at 1000 x g for 3 minutes. 
The supernatant was removed, and cells were resuspended in 100 µL of clear RPMI-1490 with 
1X (v/v) Penicillin/Streptomycin/Glutamine (P/S/Q), 6% human pooled plasma and 0.15 
µL/mL of doxycycline. 
 
2.2.2.4 C. ALBICANS GROWTH CURVE 
C. albicans overnight cultures were diluted in YPD (with 0.05 µg/mL of doxycycline) to a 
starting OD595 of 0.02. 100 µL of each diluted culture was transferred into a clear flat-bottom 
96-well plate (Corning incorporated). The plate was sealed with breathable rayon film (VWR), 
and OD595 was read every 15 minutes for 24 hours at 30 °C and shaking. Then, the growth rate 






2.2.3 PLB-985 CELL CULTURE  
 
2.2.3.1 PLB-985 CELL CULTURE 
PLB-985 cells were cultured and maintained in a 25 cm2 culture flask (Corning Incorporated) 
in culture media [red RPMI-1640 with 1X (v/v) P/Q/S, 10% (v/v) FBS] at 37 °C and 5% CO2. 
To split the cells, the flask content was centrifuged at 450 x g for 5 minutes. The supernatant 
was aspirated, and the cell pellet was resuspended in either fresh culture media for maintenance 
or differentiation media for further investigations.  
 
2.2.3.2 DIFFERENTIATION AND PURIFICATION OF PLB-985 
1x106 PLB-985 cells were seeded in 3 mL of differentiation media [red RPMI-1640 with 1X 
(v/v) P/S/Q, 2.5% (v/v) FBS, 0.5% (v/v) DMF, 1X (v/v) Nutridoma-CS] per well in a 6-well 
plate (Corning Incorporated), and incubated at 37 °C and 5% CO2 for 6 days. On day 4 of 
differentiation, each well was topped up with 2 mL of differentiation media. Cells were 
harvested on day 6 of differentiation. Cells were centrifuged at 400 x g for 10 minutes. The 
supernatant was discarded, and the concentrated cell pellet was resuspended in 1 mL of assay 
media [clear RPMI-1640 with 1% (v/v) FBS, 0.5% (v/v) DMF, 2 mM Q]. Then, cells were 
layered on top of 3 mL of Histopaque 1077 and centrifuged at 800 x g for 20 minutes. 
Differentiated PLB-985 cells floating on top of Histopaque 1077 were collected and washed 
with 3 mL of assay media and centrifuged at 400 x g for 10 minutes. The supernatant was 
aspirated, and the cell pellet was resuspended in 1 mL of 1X (w/v) PBS. Cells were then 





2.2.4 PRIMARY HUMAN NEUTROPHIL ISOLATION 
 
2.2.4.1 ETHICAL STATEMENT 
Blood samples from healthy volunteers were collected by trained staff from the Bristol Platelet 
Group (Poole and Hers laboratories). Human blood collection was approved by an NHS 
Research Ethics Committee, and all donors provided written informed consent.  
 
2.2.4.2 NEUTROPHIL ISOLATION USING DENSITY GRADIENT METHOD 
Blood samples from healthy donors were overlayed on top of Histopaque 1119 in a 1:1 ratio 
and centrifuged at 800 x g for 20 minutes. Neutrophil’s layer was collected and washed with 
0.2% HSA in 1X (w/v) PBS in a 1:2 ratio and centrifuged at 400 x g for 10 minutes. The 
supernatant was then aspirated. The cell pellet was resuspended in 1 mL of 0.2% HSA in 1X 
(w/v) PBS, layered on top of PercollTM gradients (from 85% to 65%) and centrifuged at 800 x 
g for 20 minutes. Neutrophil’s layer was collected and washed with 0.2% HSA in 1X (w/v) 
PBS in a 1:2 ratio and centrifuged at 400 x g for 10 minutes. The supernatant was aspirated. 
Neutrophil’s pellet was resuspended in 0.2% HSA in 1X (w/v) PBS, ready for subsequent 
experiments.  
 
2.2.4.3 NEUTROPHIL ISOLATION USING THE EASYSEPTM MAGNET NEGATIVE 
SELECTION METHOD (STEMCELLTM TECHNOLOGIES) 
50 µL/mL of EasySepTM Direct Human Isolation Cocktail and EasySepTM Direct 
RapidSphereTM 50300 were mixed with blood samples from healthy donors in a 14 mL Falcon® 
polystyrene round-bottom tube (Thermo Scientific) and incubated for 5 minutes at room 
temperature. The sample tube was topped up and mixed with magnetic separation media [1 
mM of EDTA in 1X (w/v) PBS, free from Ca2+ and Mg2+] to either 10 mL for samples < 4 mL 
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or 12 mL for samples ≥ 4 mL. The tube was then placed into the EasySepTM magnet and 
incubated for 10 minutes at room temperature. The enriched neutrophil suspension was 
collected into a new tube, mixed with the same volume of EasySepTM Direct RapidSphereTM 
50300 and incubated for 5 minutes at room temperature. The new tube was placed into the 
magnet and incubated for 5 minutes at room temperature for the second separation. The 
enriched neutrophil suspension was collected into a new tube and placed into the magnet for 
another 5 minutes for the final separation. The enriched neutrophil suspension was collected 
and centrifuged at 400 x g for 10 minutes. The supernatant was aspirated. Neutrophil’s pellet 
was resuspended in 0.2% HSA in 1X (w/v) PBS, ready for subsequent experiments.  
 
2.2.5 C. ALBICANS – NEUTROPHIL KILLING ASSAYS 
 
2.2.5.1 OPTIMISATION: CALCOFLUOR WHITE VS. ALAMARBLUETM STAINING  
The WT overnight culture was diluted with 1X (w/v) PBS to obtain either 3 x 104 cells/well, 
1.5 x 105 cells/well or 3 x 105 cells/well, using Eppendorf BioSpectrometer® basic. Each 
diluted culture was split into two tubes with equal volumes, where one tube was heat-killed by 
incubating in the water bath at 65°C for 30 minutes. Then, 90 µL of cell suspension of each 
culture was added into the wells of a black 96-well plate (Corning incorporated). 10 µL of 
either 10X (w/v) Calcofluor White (CFW) or 10X (w/v) alamarBlueTM was added into the 
appropriate wells. Using the FLUOstar Omega Microplate Reader (BMG LABTECH), 
fluorescence was recorded for 30 minutes in 5 minutes intervals for CFW (360/460 nm, 500 





2.2.5.2 OPTIMISATION: WILD TYPE KILLING ASSAY   
50 µL of WT cell suspension [in clear RPMI-1640 with 1X (v/v) P/S/Q, 6% human pooled 
plasma and 0.15 µg/mL of doxycycline], of either MOI of 1 (3 x 104 cells), MOI of 5 (1.5 x 
105 cells) or MOI of 10 (3 x 105 cells), was added to the wells of a black 96-well plate (Corning 
Incorporated). 100 µL of neutrophils or PLB-985 suspension (3 x 105 cell/mL in RPMI-1640) 
was added to the wells of the black 96-well plate. 100 µL of RPMI-1640 was added to the wells 
without neutrophils or PLB-985. The plate was then incubated at 37°C and 5% CO2 for 2.5 
hours. After incubation, either CFW or alamarBlueTM assays were carried out (see section 
2.2.5.5-6). 
 
2.2.5.3 GRACETM LIBRARY SCREENING  
50 µL of subcultures (see section 2.2.2.3) was added into the wells of black 96-well plates 
(Corning Incorporated). 100 µL of PLB-985 suspension (3 x 105 cell/mL in clear RPMI-1640) 
was added to the appropriate wells of these black 96-well plates. 100 µL of clear RPMI-1640 
was added to the wells without PLB-985. The plate was then incubated at 37°C and 5% CO2 
for 2.5 hours. After incubation, the alamarBlueTM assay was carried out (see section 2.2.5.5). 
 
2.2.5.4 VALIDATION SCREEN OF SUSCEPTIBLE MUTANTS  
50 µL of WT or mutant cell suspension [1.5 x 105 cells or MOI of 5, in clear RPMI-1640 with 
1X (v/v) P/S/Q, 6% human pooled plasma and 0.15 µg/mL of doxycycline] was added to the 
wells of a black 96-well plate (Corning Incorporated). 100 µL of neutrophil suspension (3 x 
105 cell/mL in clear RPMI-1640) was added to the wells of the black 96-well plate. 100 µL of 
RPMI-1640 was added to the wells without neutrophils. The plates were then incubated at 37°C 
and 5% CO2 for 2.5 hours. After incubation, the alamarBlueTM assays were carried out (see 
section 2.2.5.5).   
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2.2.5.5 ALAMARBLUETM ASSAY 
After 2.5 hours of incubation, plates were centrifuged at 1000 x g for 3 minutes. 100 µL of 
supernatant was removed, and 50 µL of 0.1% Triton X-100 in ddH2O was added to the wells. 
The plates were centrifuged at 1000 x g for 3 minutes after 5 minutes incubation with Triton 
X-100. 100 µL of supernatant was removed from the wells, and wells were washed three times 
with 100 µL of 1X (w/v) PBS. Lastly, 90 µL of 1X (w/v) PBS [with 1X (v/v) P/S/Q] and 10 
µL of 10X (w/v) alamarBlueTM were added to each well, and then the plates were incubated at 
37°C and 5% CO2 for 14-15 hours. The FLUOstar Omega Microplate Reader (BMG 
LABTECH) was used to read the plate by recording fluorescence at 544/590 (gains: 1000). 




(&. ()*+,(-. + Neutrophils	or	PLB_985) − (Neutrophils	or	PLB_985	only)
(&. ()*+,(-.	only) − (RPMI_1640	only)
M x	100 
 
2.2.5.6 CALCOFLUOR WHITE ASSAY 
The protocol is similar to the alamarBlueTM assay. However, 90 µL of 1X (w/v) PBS [with 1X 
(v/v) P/S/Q] and 10 µL of 10X (w/v) CFW were added to the well (after 14-15 hours of 
incubation) and incubated at room temperature for 10 minutes. Then, cells were fixed with 2% 
PFA for 20 minutes and washed two times with 100 µL of 1X (w/v) PBS. The FLUOstar 
Omega Microplate Reader (BMG LABTECH) was used to read the plate by recording 





2.2.6 C. ALBICANS SERUM-INDUCED FILAMENTATION ASSAY 
 
2.2.6.1 C. ALBICANS FOETAL BOVINE SERUM (FBS)-INDUCED 
FILAMENTATION ASSAY  
C. albicans overnight cultures were diluted to an OD600 of 0.2 in YPD media (with 0.05 µg/mL 
of doxycycline). The diluted cultures were grown for a further 4 hours at 30 °C and 200 rpm. 
After 4 hours of incubation, the cultures were diluted to an OD600 of 0.2 in YPD media (with 
0.05 µg/mL of doxycycline and 10% FBS) and incubated for 2 hours at 37 °C and 200 rpm. 
Leica DMI6000 wide-field microscopy [in differential interference contrast (DIC) mode] was 
used to take images of each culture before and after FBS was added. Then, the average 
morphology index (of 30 cells per image) was calculated (Merson-Davies and Odds, 1989).  
 
2.2.7 C. ALBICANS OXIDATIVE STRESS ASSAY  
 
2.2.7.1 C. ALBICANS H2O2 OXIDATIVE STRESS ASSAY  
After 4 hours of incubation (see section 2.2.6), each C. albicans strain was diluted with 1X 
(w/v) PBS (with 0.05 µg/mL of doxycycline) to 2 x 104 cell/mL. Each cell solution was further 
divided into three 5 mL in glass culture tubes. Tube 1 was diluted 1: 10 in 1X (w/v) PBS (with 
0.05 µg/mL of doxycycline), and 100 µL of the solution were plated onto three YPD agar 
plates. Tube 2 and 3 were incubated with or without 0.1 mM (w/v) H2O2, respectively, for 1 
hour at 37 °C and 200 rpm. After incubation, each tube was diluted 1: 10 in 1X (w/v) PBS 
(with 0.05 µg/mL of doxycycline) and 100 µL of the solution were plated onto three YPD agar 
plates. YPD agar plates were incubated at 30 °C for 2 days, and the survival rate of each strain 
was calculated based on the colony-forming unit (CFU) counts.  
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2.2.8 C. ALBICANS CELL WALL STRESS ASSAY 
 
2.2.8.1 C. ALBICANS CELL WALL STRESS ASSAY USING CALCOFLUOR WHITE 
AND CONGO RED 
After 4 hours of incubation (see section 2.2.6), C. albicans was diluted with 1X (w/v) PBS 
(with 0.05 µg/mL of doxycycline) to an OD600 of 0.1. It was then further diluted to six serial 
10-fold dilutions in 1X (w/v) PBS (with 0.05 µg/mL of doxycycline). 5 µL of each dilution 
was spotted onto the following agar plates (pH 5.5 – 7.0): YPD control, 75 µg/mL of Congo 
Red YPD, 100 µg/mL of CFW YPD. These plates were incubated at 30 °C for 3 days.  
 
2.2.9 OXIDATIVE BURST ASSAY 
 
2.2.9.1 MEASURE OXIDATIVE BURST USING LUMINOL METHOD 
1x105 PLB-985 or neutrophils were seeded in 100 µL of ROS media [HBSS (with Ca2+ and 
Mg2+), 1X (v/v) HEPES and 0.025% (v/v) HSA] in a white 96-well plate (Costar). 11 µl of a 
mixture of HRP (stock concentration of 1200 U/mL) and Luminol (stock concentration of 50 
mM) diluted 1:200 in ROS media was added to the cells, and the plate was incubated at 37 °C 
and 5% CO2 for 15 minutes. After that, cells were stimulated with either 100 nM of Phorbol 
12-myristate 13-acetate (PMA) or C. albicans (MOI of 5) or unstimulated. The FLUOstar 
Omega Microplate Reader (BMG LABTECH) was used to read the plate by recording 
chemiluminescence for 4 hours in 2 minutes intervals. The area under the ROS kinetic curves 





2.2.10 NETOSIS ASSAY 
 
2.2.10.1 MEASUREMENT OF NEUTROPHIL EXTRACELLULAR TRAP (NET) 
FORMATION USING SYTOXTM DYES 
100 µL of WT or mutant cell suspension [MOI of 5, in NETs assay media (0.025% HSA, 
10mM HEPES in clear RPMI-1640), with 2% human pooled plasma and 0.05 µg/mL of 
doxycycline] was added to the wells of a black 96-well plate (Corning Incorporated) and 
incubated at 37°C and 5% CO2 for 2 hours (until exhibit filamentous morphology). Then, 50 
µL of neutrophil suspension (6 x 105 cell/mL in NETs assay media, with 2% human pooled 
plasma and 0.05 µg/mL of doxycycline) was added to the wells of the black 96-well plate. The 
plate was then incubated at 37°C and 5% CO2 for 2 hours. After incubation, 1 µM of SYTOXTM 
Orange and 100 nM of SYTOTM Green were added to all wells, and the plate was imaged using 
EVOS FL Cell Imaging System (Thermo Fisher Scientific). Then, the number of NETs per 
image was calculated based on SYTOXTM Orange images.  
 
2.2.11 STATISTICAL ANALYSIS 
 
GraphPad Prism 9 was used to assess the Gaussian distribution of all data sets, using the 
Shapiro-Wilk test and Q-Q plot, and all data sets were found to be normally distributed. For 
group comparison, One- or Two-way ANOVA (depending on each data set condition) was 
used except for those with unequal variance where Welch’s t-test was performed. Multiple t-
test analysis was used to compare two groups over a time course. In all cases, *p<0.05 
denoted statistical significance.   
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CHAPTER 3: KILLING ASSAY OPTIMISATION 
 
3.1 INTRODUCTION  
 
Different methods exist to quantify Candida killing by neutrophils; they include colorimetric-
based assays as well as colony-forming units (CFU) based assays (Cihlar and Calderone, 2009). 
For my project, I have chosen to perform a chemiluminescence-based killing assay due to the 
high throughput nature of my experiment using either alamarBlueTM cell viability reagent or 
Calcofluor white staining.  
 
alamarBlueTM reagent is a resazurin-based solution. Resazurin is a cell-permeable non-toxic 
compound. The reagent is irreversibly reduced from non-fluorescent blue resazurin to highly 
fluorescent red resorufin by the respiration of active cells (Rampersad, 2012, Chen et al., 2015). 
This means that its fluorescence indicates cell metabolic activity, which correlates to cell 
viability (i.e., the greater the fluorescence, the more viable cells) (Rampersad, 2012). 
Calcofluor White (CFW) is a fluorescent deep blue dye that can detect C. albicans by binding 
to cellulose and chitin components of the cell wall (Harrington and Hageage, 2003). Its 
fluorescence signal correlates to cell abundance (i.e., the greater the fluorescence, the greater 
the cell population). Therefore, these two reagents represent promising candidates for the 
GRACETM library screen.  
 
Due to the high quantity of neutrophils required to screen the GRACETM library that consisted 
of 2,357 mutants (Merk & Co.) and a limited supply of primary human neutrophils, the PLB-
985 cell line was chosen to use in the initial library screen. PLB-985 is an acute myeloid 
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leukaemia cell derived from the HL-60 cell line. It can be differentiated to neutrophil-like cells 
by stimulating the cells with DMF (see section 2.2.3), which have been shown to have similar 
morphology and exert similar functions to neutrophils against pathogens (Pedruzzi et al., 2002, 
Pivot-Pajot et al., 2010). Thus, the PLB-985 cell has the potential to be used in the initial 
GRACETM library screen as an alternative cell to neutrophils.  
 
This chapter aimed to optimise a C. albicans killing assay for the GRACETM library screen, 
with the following objectives:  
• Optimising high throughput chemiluminescence-based killing assays using 
alamarBlueTM and CFW reagents 
• Establishing PLB-985 cells as a model for C. albicans killing assay 




3.2.1 ALAMARBLUETM REQUIRES A LONGER INCUBATION 
PERIOD THAN CALCOFLUOR WHITE   
 
Before incorporating alamarBlueTM and CFW into the killing assay, it was important to 
optimise a suitable incubation period for each reagent. Therefore, live and heat-killed WT 
(CaSS1) C. albicans cells were incubated with either alamarBlueTM over 24 hours or CFW 
over 30 minutes, according to the recommended times stated in the instruction manuals. 
 
The alamarBlueTM fluorescence (RFU) signal of live cells continuously increased over the 24 
hours of incubation, while this increase was not detected in heat-killed cells (Figure 3.1a). Live 
cells at a concentration of 1.5 x 106 cell/mL and 3 x 106 cell/mL appeared to have a significantly 
greater fluorescence (RFU) signal than the heat-killed cells at the same concentration from 12 
hours and 8 hours onwards, respectively (Figure 3.1a.). Interestingly, this phenomenon was not 
observed in cells at a 3 x 105 cell/mL concentration.  
 
The CFW fluorescence (RFU) signal of both live and heat-killed cells appeared to decrease 
continuously over 30 minutes of incubation (Figure 3.1b). This increase was not prominent in 
live cells compared to heat-killed cells as the fluorescent signal of all live cell concentrations 
had an overlap of the standard error of the mean (SEM) after 5 minutes. Unexpectedly, live 
cells at a concentration of 1.5 x 106 cell/mL and 3 x 106 cell/mL appeared to have a significantly 
greater fluorescence signal than the heat-killed cells at the same concentration after 10 and 5 
minutes of incubation, respectively.  
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Therefore, I decided to choose 14-15 hours incubation time for alamarBlueTM and 10 minutes 







Figure 3.1: alamarBlueTM vs. Calcofluor White incubation periods. (a.) alamarBlueTM 
fluorescence of live and heat-killed WT (CaSS1) C. albicans over 24 hours. (b.) CFW 
fluorescence of live and heat-killed WT over 30 minutes. Fluorescence (mean in RFU) ± SEM 
(Standard error of mean). Statistical significance was calculated by 2-tailed multiple paired t-
test comparison; #, * p<0.05, ###, *** p<0.001; * comparison between live and heat-killed 3 
x 106 cell/mL; # comparison between live and heat-killed 1.5 x 106 cell/mL; n=3.  
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3.2.2 ALAMARBLUETM REAGENT IS MORE SENSITIVE THAN 
CALCOFLUOR WHITE STAINING  
 
Having established the incubation time for each reagent, I next examined their sensitivity in 
detecting C. albicans killing by PLB-985 and neutrophils. WT cells at the MOI of 1, 5 or 10 
were co-incubated with or without either neutrophils or PLB-985, then either CFW or 
alamarBlueTM assays were carried out (see 2.2.5.2 and Figure 3.2).  
 
The alamarBlueTM fluorescence signal of cells at the MOI of 5 treated with PLB-985 was 
significantly lower than those without PLB-985, while this difference was not detected for cells 
at the MOI of 1 and 10 groups (Figure 3.3a). Similarly, the alamarBlueTM fluorescence signals 
of cells at the MOI of 1 and 5 co-incubated with neutrophils were significantly lower than those 
without neutrophils (Figure 3.3b). However, there was no significant between the CFW 
fluorescence signals of cells at the MOI of 1, 5, 10 co-incubated with PLB-985 or neutrophils 
and without PLB-985 or neutrophils (Figure 3.3c-d).  
 
Therefore, I decided to only use alamarBlueTM reagent as part of my GRACETM library screen 
as the data revealed that alamarBlueTM has a higher sensitivity at detecting neutrophil killing 
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Figure 3.3: alamarBlueTM provided more sensitive detection of C. albicans killing by 
neutrophils than Calcofluor White (CFW). (a.) alamarBlueTM fluorescence of CaSS1-PLB-
985 killing assay (KA). (b.) alamarBlueTM fluorescence of CaSS1-neutrophil KA. (c.) CFW 
fluorescence of CaSS1-PLB-985 KA. (d.) CFW fluorescence of CaSS1-neutrophil KA. 
Fluorescence (mean in RFU) ± SEM. Statistical significance was calculated by 2-way 





3.2.3 PLB-985 CELLS ARE SIMILAR TO PRIMARY HUMAN 
NEUTROPHILS AT KILLING C. ALBICANS 
 
To establish PLB-985 effectiveness at killing C. albicans compared to neutrophils, WT C. 
albicans cells were co-incubated with or without either PLB-985 or neutrophils. After the 
killing assay with alamarBlueTM was carried out (see section 2.2.5), the percentage metabolic 
rate of C. albicans was calculated based on the fluorescence signals of PLB-985/neutrophil and 
non-PLB-985/neutrophil treatment groups.  
 
The data revealed that the higher the MOI, the greater the percentage metabolic rate of WT 
strain (Figure 3.4). This, in turn, suggested that there were more viable C. albicans cells at a 
higher MOI after being challenged with neutrophils or PLB-985. WT cells that were challenged 
with neutrophils had a lower percentage metabolic rate at the MOI of 1 (by ~23%) and 5 (by 
~20%), and a higher percentage metabolic rate at the MOI of 10 (by 7%) than those that were 
challenged with PLB-985. However, these differences were not statistically significant except 
for the MOI of 1 (Figure 3.4). Therefore, this suggested that PLB-985 cells are only slightly 
less efficient at killing C. albicans as neutrophils.  
 
Having shown that PLB-985 cells were similar to neutrophils at killing C. albicans, I next 
investigated a suitable C. albicans cell ratio to neutrophils/PLB-985 for the GRACETM library 
screen. The MOI with the closest to 50% metabolic rate was chosen to use in my screen, as this 
would allow a change in either direction to be detected to determine whether a mutant was 
susceptible to PLB-985 or neutrophils compared to WT strain. MOI of 5 was chosen for both 




Figure 3.4: PLB-985 exhibited a similar level of C. albicans killing to neutrophils. The 
graph shows the metabolic rate (%) of CaSS1 with either PLB-985 or neutrophils at MOI of 1, 







3.2.4 PLB-985 CELLS ARE SIMILAR TO NEUTROPHILS AT 
PRODUCING REACTIVE OXYGEN SPECIES 
 
Having established a suitable MOI, respiratory burst assays were carried out to assess another 
function of PLB-985 compared to neutrophils by challenging PLB-985 or neutrophils with C. 
albicans (WT) at the MOI of 5. Reactive oxygen species (ROS) production is one of the main 
neutrophil antifungal responses against C. albicans (Jamieson et al., 1996, Segal, 2005). 
Therefore, it was important to examine the ability of PLB-985 cells to produce ROS.  
 
The kinetic curves showed that PLB-985 produced an earlier ROS burst with an overall lower 
ROS chemiluminescence signal (~ 1/3 less based on ROS peak values) than neutrophils when 
stimulated with PMA, a potent non-physiological chemical inducer (Figure 3.5a). Similarly, 
when stimulated with C. albicans, PLB-985 started to produce a ROS burst simultaneously 
with neutrophils but with an overall lower ROS chemiluminescence signal (~ 1/2 less based on 
ROS peak values) (Figure 3.5c). These effects were also observed when areas under the kinetic 
curve were calculated. However, the area under the kinetic curve showed no significant 
difference in the total ROS production between PLB-985 and neutrophils when stimulated with 
PMA or C. albicans (Figure 3.5b, d). This implied that PLB-985 cells were able to produce 







Figure 3.5: PLB-985 cells showed reduced respiratory burst against C. albicans compared 
to neutrophils. (a.) Chemiluminescence of reactive oxygen species (ROS) signal of PLB-985 
or neutrophils with PMA. (b.) The area under the ROS curve of (a). (c.) Chemiluminescence 
of ROS signal of PLB-985 or neutrophils with CaSS1. (d.) The area under the ROS curve of 
(c). Chemiluminescence (mean in RFU) ± SEM; Area under the curve (mean) ± SEM. 
Statistical significance was calculated by 2-way ANOVA; *p<0.05, **p<0.01, ***p<0.001; 
n=4. PLB-985 and neutrophils were challenged with WT C. albicans at MOI of 5 (see section 
2.2.9). 
 






















































































































The studies presented in this chapter aimed to optimise the C. albicans killing assay for the 
GRACETM library screen and establish PLB-985 as a potential model in the C. albicans killing 
assay.  
 
alamarBlueTM fluorescence signal correlates to cell metabolic activity, indicating cell viability 
as only active cells can reduce the alamarBlueTM from non-fluorescent blue to fluorescent red 
colour (Rampersad, 2012, Chen et al., 2015). The CFW fluorescence signal correlates to 
biomass abundance (of live or dead cells) as it only stains the fungal cell wall (Harrington and 
Hageage, 2003). I initially anticipated that if more C. albicans cells survived after being 
challenged with PLB-985 and neutrophils, there would be more cell wall surface to bind to the 
CFW. Thus, cell abundance based on CFW staining may be able to predict cell viability.  
 
14-15 hours of alamarBlueTM incubation was chosen as my data revealed that this incubation 
period was sufficient to distinguish between live and heat-killed cells. However, later 
incubation time points offered a greater significant difference, this time point was chosen for 
the killing assay to prevent the overshoot of “over incubation” of cells with alamarBlueTM. My 
data revealed that the alamarBlueTM signal plateaued and decreased at a higher cell 
concentration over a more extended incubation period (Supplementary figure 1a). It is not well 
understood why this phenomenon occurred as the reduction of resazurin to resorufin is 
irreversible (Chen et al., 2015). However, a plateau signal was expected as all resazurin in the 
solution has been reduced. One plausible explanation could be that over time C. albicans 
started to change their metabolism and switch on anaerobic respiration due to cell stress in 
response to overpopulation and lack of nutrients. This, in turn, may have caused the media to 
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become acidic and cause resorufin to reversibly reduce to the non-fluorescent dihydroresorufin 
(çakır and Arslan, 2010, Chen et al., 2015). Another explanation could be that C. albicans may 
have the ability to break down resazurin. Due to the extensive screening scale of the GRACETM 
library (96 mutants per plate), it was impossible to dilute each mutant to the exact required 
MOI number. This means that more or fewer cells might be added to the wells, and thus would 
affect the alamarBlueTM reduction reaction (see section 2.2.2.2 and Chapter 4). Also, the 
metabolic activity of each mutant in the GRACETM library was unknown. This is another 
important factor that could affect the reduction rate of resazurin. Therefore, 14-15 hours of 
alamarBlueTM incubation was chosen as it provided good resolution and avoided fungal 
overgrowth.  
 
10 minutes of CFW incubation was chosen as my data revealed no or little difference between 
fluorescence signals after 5 minutes for live cells. Thus, this suggested that this incubation 
period was sufficient for the dye to stain all cell walls. However, all samples showed decreased 
fluorescence over time. This could be due to over and frequent excitation, which causes CFW 
dye to lose its fluorescence signal. However, this does not fully explain the dramatic decrease 
of the heat-killed cells. Interestingly, live cells at a higher cell concentration had a significantly 
higher fluorescence signal than heat-killed cells (Supplementary figure 1b). This was an 
unexpected observation as C. albicans cells were only incubated for a short period and not at 
their optimum growth conditions (see section 2.2.5.1). Therefore, it was unlikely for the live 
cells to outgrow the heat-killed cells in the given 30 minutes. One explanation for this 
observation could be that high temperature perhaps caused C. albicans to lose its ability to 
maintain cell wall integrity and caused cell wall structure alterations, for example, by inducing 
the breakdown of C. albicans cell wall components (such as b-glycans and glycoproteins) or 
denaturing enzymes that are required to maintain cell wall structure (Garcia-Rubio et al., 2019, 
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Gazendam et al., 2016). Therefore, the dye may have been unable to bind to the cell wall 
properly and hence a lower signal.  
 
The alamarBlueTM killing assay with WT cells revealed significant killing of C. albicans at the 
MOI of 5 by PLB-985. However, the CFW killing assay with WT cells showed no killing of 
C. albicans by PLB-985. Since both reagents did not give a similar result in terms of reporting 
PLB-985 ability to kill C. albicans, the question of each reagent sensitivity was raised. It was 
impossible to compare reagent sensitivity based on PLB-985 killing assay data as it was 
unknown if PLB-985 cells can effectively kill C. albicans. Therefore, C. albicans killing assays 
with primary human neutrophils were performed to compare the dyes’ sensitivity. Neutrophils 
are cells that have been confirmed to have the ability to kill C. albicans (Gazendam et al., 
2016). The alamarBlueTM killing assay reported a significant killing of C. albicans at the MOI 
of 1 and 5, while this observation was not reported in the CFW killing assay. This showed that 
the alamarBlueTM reagent was more sensitive than CFW at detecting C. albicans killing by 
PLB-985 and neutrophils. This observation was expected because the alamarBlueTM 
fluorescence signal directly correlates to cell viability. Although CFW has a higher specificity 
to C. albicans, it failed to detect cell viability. One possible explanation for this outcome could 
be that the neutrophils failed to degrade C. albicans components of dead cells completely. A 
study showed that neutrophils could release NETs to trap and kill C. albicans, as an alternative 
killing method to phagocytosis, a “traditional” mechanism that degrades C. albicans 
components (Branzk et al., 2014). This means there will be dead C. albicans cells with intact 
cell walls, which will get picked up by the CFW fluorescence signal. Thus, alamarBlueTM was 
chosen for the screen to detect C. albicans viability. However, it should be used with caution 
due to its low specificity.  
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To assess PLB-985 ability to kill C. albicans, cell viability was determined based on the 
percentage metabolic rates of C. albicans after being exposed to PLB-985 and neutrophils. The 
data revealed that PLB-985 cells were slightly less efficient at killing C. albicans than 
neutrophils at the MOI of 1 and 5 with ~23% and ~20% more viable cells, respectively. 
However, the difference was only statistically significant at the MOI of 1. The data also showed 
no or negligible killing at the MOI of 10 for both PLB-985 and neutrophils. This is likely 
because there were too many C. albicans cells to be killed. Also, these C. albicans cells will 
exert “anti-neutrophil” responses to escape from neutrophil killing (see section 1.3). Thus, it 
will be more challenging for neutrophils or PLB-985 to deal with a great abundance of C. 
albicans. Overall, the killing assay data revealed that PLB-985 could effectively kill C. 
albicans depending on the MOI of C. albicans.  
 
MOI of 5 was chosen for both PLB-985 and neutrophils as the most appropriate for the 
GRACETM library screen. It offered the closest to 50% metabolic rate for neutrophils, allowing 
changes in either direction to be detected. For PLB-985 cells, the metabolic rate was ~77% at 
the MOI of 5. According to the percentage metabolic rate, the MOI of 5 is not an ideal choice 
for PLB-985 compared to the MOI of 1 that had ~57% metabolic rate. However, there was no 
significant C. albicans killing by PLB-985 cells at the MOI of 1, which suggested that the MOI 
of 1 was not a suitable MOI despite having a value closer to 50%.  
 
Previous research demonstrated that PLB-985 cells could perform similar functions to 
neutrophils, such as the ability to perform phagocytosis, ROS production and NETosis to some 
pathogens and stimuli (Pedruzzi et al., 2002, Pivot-Pajot et al., 2010, Volk et al., 2011). The 
ROS kinetic curves showed that PLB-985 cells could produce a ROS burst in response to C. 
albicans and PMA stimulation with an overall lower total ROS production and ROS peak than 
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neutrophils. Interestingly, the area under the kinetic curves revealed that the difference in ROS 
production between neutrophils and PLB-985 cells was not statistically significant. It is worth 
mentioning that the area under the curve is correlated to the total ROS production. Therefore, 
it does not give any information on how potent or toxic the ROS contents produced by PLB-
985 are to C. albicans compared to neutrophils. The concentration of ROS in a specific time 
point (e.g., the peak of the kinetic curve) may give a better indication of the ROS potency and 





3.4 CONCLUSION  
 
My data revealed that PLB-985 cells were a good model to use in the initial GRACETM library 
screen as they were potent at killing C. albicans. As they are originated from a single clone 
and grown in the laboratory, there are fewer genetic variations and differences in in vivo 
priming between PLB-985 cells than neutrophils of different donors, which could influence 
how cells respond to pathogens.  
 
This project is the first study to date to establish PLB-985 cells as a model for C. albicans 
killing assays and reveal their potential to be used in place of neutrophils when these are 
unavailable. Also, this is one of the first investigations to date (if not the first) to report the 
interaction between PLB-985 cells and C. albicans, such as their ability to kill C. albicans and 





CHAPTER 4: THE GRACETM LIBRARY SCREEN 
 
4.1 INTRODUCTION  
 
The GRACETM (gene replacement and conditional expression) library is a non-redundant 
library that contains 2,357 C. albicans mutants (one mutant per gene) (Merk & Co). The library 
was created based on the tetracycline (Tet)-regulatable promoter system, whereby one allele of 
a target gene (of a diploid C albicans strain called CaSS1) was deleted, and the other copy was 
then placed under the control of a Tet repressive promoter. Tet analogues, such as doxycycline, 
inhibit target gene expression completely and thus inhibit its downstream functions (Roemer 
et al., 2003). Previous research successfully utilised the GRACETM library to reveal novel 
information about C. albicans functions and its interaction with other immune cells, such as 
macrophages (Edouarzin et al., 2019, Lee et al., 2016, O'Meara et al., 2018, O'Meara et al., 
2015, Xu et al., 2019). Therefore, screening the GRACETM library with PLB-985 or neutrophils 
could help us better understand C. albicans interaction with neutrophils.  
 
The research aim of this chapter was to identify C. albicans genetic factors that are important 
for the survival of neutrophil antifungal responses by screening the GRACETM library. This 
chapter research objectives were:  
• Estimate a suitable subcultured volume of GRACETM library mutants to achieve an 
MOI of 5 
• Identify GRACETM library mutants that were susceptible to PLB-985 killing 





4.2.1 THE OPTIMISATION OF A REQUIRED SUBCULTURED 
VOLUME FOR THE GRACETM LIBRARY SCREEN 
 
As the GRACETM library is arrayed in a 96-well plate format (i.e., each well represents one 
mutant), it was not possible to dilute each strain to the MOI of 5 when performing the killing 
assay. To overcome this challenge, CaSS1 (WT) was incubated overnight and subcultured in a 
96-well plate (see section 2.2.2.2). After subculturing, the OD595 of the plate was measured and 
used to calculate the number of cells, using OD595 of 1 = 1 x 107 cell/mL. The estimated volume 
of C. albicans suspension (containing MOI of 5 or 150,000 cells) was further determined. 
Figure 4.1 showed that the greater the dilutions, the greater the volume required to achieve an 
MOI of 5. For convenience purposes, 50 µL of undiluted subculture was chosen to add to the 







Figure 4.1: The required GRACETM volume to achieve MOI of 5. The graph shows the 
estimated volume of C. albicans subcultured suspension containing 150,000 cells. Volume 








4.2.2 THE GRACETM LIBRARY MUTANTS ARE SUSCEPTIBLE 
TO PLB-985 KILLING 
 
To identify C. albicans mutants susceptible to neutrophils, I first screened the GRACETM 
library with PLB-985 cells and determined the mutant metabolic rate based on the 
alamarBlueTM fluorescence signal (see section 2.2.5.3 and Figure 4.2). The percentage 
metabolic rate is correlated to cell viability. Therefore, mutants susceptible to PLB-985 (or 
neutrophils) would have a lower percentage metabolic rate than the WT control.  
 
Figure 4.3-4.6 show the percentage metabolic rate of C. albicans mutants from GRACETM 
plates 1, 2, 7 and 11 with their internal WT controls (these plates were randomly selected). Six 
mutants (A12, B12, E07, G06 and G12) from plate 1 had a lower percentage metabolic rate 
than their internal WT control, while ~58 mutants had a higher percentage metabolic rate than 
the control (Figure 4.3). Similarly, 2 mutants (F12 and H11) from plate 2 had a lower 
percentage metabolic rate than their internal control, while ~46 mutants had a higher 
percentage metabolic rate than the control (Figure 4.4). Likewise, 7 mutants (A09, D07, F02, 
G03, H0, H04 and H11) from plate 7 were found to have a lower percentage metabolic rate 
than their WT control, while ~52 mutants had a higher percentage metabolic rate than the 
control (Figure 4.5). Comparably, 8 mutants (A01, A03, B01, B02, B05, B10, C01 and C02) 
from plate 11 were shown to have a lower percentage metabolic rate than their internal control, 
while ~42 mutants had a higher percentage metabolic rate than the WT (Figure 4.6). 
Interestingly, ~36% of all mutants screened across the four plates were found to have >100% 
metabolic rate (41 mutants from plate 1, 29 mutants from plate 2, 42 mutants from plate 7 and 
28 mutants from plate 11).  
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The 23 C. albicans mutants (as summarised in Table 4.1) with greater susceptibility to PLB-
985 cells were chosen to be further validated with neutrophils. As more than 50% of all mutants 
screened had a greater percentage metabolic rate than the WT control, I also randomly chose 2 
mutants with a small standard error of the mean (D07 and G02 from plate 2) to be validated 
with neutrophils. Not only did these 2 mutants have a greater percentage metabolic rate than 
their internal WT control, but they also had an unusual >100% metabolic rate. Validating these 
two mutants could help me to assess the potential use of my optimised GRACETM screen assay 
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GRACETM Plate Position 
1 A12 B12 E07 E08 G06 G12 
  
2 F12 H11 D07 G02 
    
7 A09 D07 F02 G03 H03 H04 H11 
 
11 A01 A03 B01 B02 B05 B10 C01 C02 
 
Table 4.1: GRACETM mutants that were chosen to be further validated with neutrophils. 
Table 4.1 shows GRACETM mutants that were susceptible to PLB-985 cells (i.e., those that had 
a lower percentage metabolic rate than the WT control) from plates 1, 2, 7 and 11 (except for 
D07, G02 from plate 1 (highlighted in yellow), where their metabolic rate was higher than WT 
control and >100%). These mutants were then individually validated with neutrophils once, 
and any mutants with a lower percentage metabolic rate than the WT control (highlighted in 






4.2.3 FOUR GRACETM MUTANTS ARE SUSCEPTIBLE TO 
PRIMARY HUMAN NEUTROPHILS 
 
The identified GRACETM mutants susceptible to PLB-985 cells (highlighted in Table 4.1) were 
individually screened with neutrophils once (see section 2.2.5.4). Overall, 11 out of 23 
previously identified mutants were shown to be susceptible to neutrophils after the first 
validation (Figure 4.7). Interestingly, the 2 mutants [D07 (57.54 ± 2.86%) and G02 (39.86 ± 
6.00%)] from plate 2 (that has previously been shown to have more than 100% metabolic rate 
after being challenged with PLB-985 cells) had a similar percentage metabolic rate to their 
internal WT control (49.66 ± 5.74%) after being challenged with neutrophils (Figure 4.7b). 
 
From the initial validation, the identified 11 promising susceptible mutants were chosen for 
further validation with neutrophils. Figure 4.8 shows the percentage C. albicans metabolic rate 
relative to the WT control of the day. The results revealed that 9 out of 11 mutants had a mean 
percentage metabolic rate below 100%. However, only four of these mutants were found to be 
statistically significant compared to the WT control. These four mutants were A12 (62.22 ± 
9.43%) from plate 2 and A01 (56.11 ± 8.53%), B10 (72.40 ± 8.46%), C02 (60.65 ± 4.26%) 
from plate11 (Figure 4.8). Interestingly, one mutant from plate 11 [B05 (73.15 ± 11.98%)] was 
found to be near significant (p=0.054) in comparison to the WT control. These five mutants 






Figure 4.7: Eleven GRACETM mutants were found to be susceptible to neutrophils after 
the first validation. (a.) Plate 1 mutants. (b.) Plate 2 mutants. (c.) Plate 7 mutants. (d.) Plate 
11 mutants. The C. albicans (MOI of 5)-neutrophil killing assays were performed, and the 
percentage (%) C. albicans metabolic rate was calculated based on alamarBlueTM fluorescence 
signals (see section 2.2.5.4). % (mean) ± SD; n=1 donor; each dot represents a technical 
replicate; mutants that were chosen to be further validated with neutrophils from 3 additional 





Figure 4.8: Four GRACETM mutants were susceptible to neutrophils. C. albicans (MOI of 
5)-neutrophil killing assays of eleven GRACETM  mutants were performed, and the percentage 
(%) C. albicans metabolic rate was calculated based on alamarBlueTM fluorescence signals (see 
section 2.2.5.4). % (mean) ± SEM is relative to the WT control of the day. Statistical 
significance was calculated by one-tailed Welch unpaired t-test; *p<0.05, **p<0.01, 
+p<0.054; n=4 donors. 
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4.2.4 GRACETM MUTANTS EXHIBIT A SIMILAR GROWTH 
RATE TO THE WT CONTROL.  
 
Having identified GRACETM mutants that were susceptible to neutrophils (see Table 4.2), I 
next measured their growth rate in comparison to the WT control. This was to identify slow-
growing phenotypes that may affect susceptibility to neutrophils. WT and mutants were 
incubated in YPD under doxycycline repression. The OD595 of the cultures were measured 
every 15 minutes over 24 hours (see section 2.2.2.4).  
 
Four mutants (F12, A01, B10 and C02) had a similar maximum growth level to the WT control, 
while B05 had a lower maximum growth level than the WT. Interestingly, only two mutants 
(F12 and B10) were shown to have a similar growth rate to the WT control, while the other 
three mutants (A01, B05 and C02) had a lower growth rate than the control (Figure 4.9 and 
Table 4.2). However, it was unclear if these differences were all biologically significant, with 





Figure 4.9: The growth curves of susceptible GRACETM mutants. WT C. albicans and 
mutants were incubated in YPD (starting OD595 of 0.02) in a clear 96-well plate at 30 oC and 
shaking for 24 hours. The OD595 of the plate was measured every 15 minutes over the 
incubation period (see section 2.2.2.4). Then, the OD595 values were plot against time. OD595 
(mean) ± SEM; n=3. 
 
  

























This chapter aimed to identify C. albicans genes that are vital for the survival of neutrophil 
antifungal responses by screening the GRACETM library.  
 
Four out of 25 GRACETM plates were initially screened with PLB-985 cells. Out of 384 
mutants screened, 23 mutants (~6%) were more susceptible to PLB-985 killing than the WT 
control. Therefore, these 23 mutants were chosen to be further validated with neutrophils. It 
was expected that not all mutants would be susceptible to PLB-985 cells because only a single 
gene was repressed. There are many genes that contribute to the ability of C. albicans to evade 
neutrophils, and some of these genes may be redundant (Niemiec et al., 2017). Therefore, only 
mutants with a repressed gene that contributes the most to the evasion strategies would show 
up as being susceptible to PLB-985 or neutrophils. 
 
Interestingly, over 50% of mutants screened were more resistant to PLB-985 cells than the WT 
control. Also, out of these “resistant” mutants, ~71% had more than 100% metabolic rate. This 
data suggested that some of these mutants were growing better with PLB-985 cells, which was 
unexpected. One explanation could be that C. albicans may have the ability to break down 
lysed-PLB-985 components and utilise these nutrients for their own growth. Another 
explanation could be that PLB-985 triggered C. albicans stress responses, causing them to 
increase their proliferation rate or be more metabolically active than usual, and thus a greater 
reduction of the alamarBlueTM reagent in PLB-985 treated wells. Also, it could be that some 
mutants were able to grow exponentially (i.e., remain in the log phase) after being challenged 
with PLB-985 cells as more cells were killed, and thus more space was available for growth. 
This exponential growth may not be possible in non-treated well as C. albicans were more 
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likely to be overgrown and remained in the stationary/death phase. Therefore, this resulted in 
a higher alamarBlueTM fluorescence signal in PLB-985 treated than non-treated wells, hence 
over 100% metabolic rate. Additionally, PLB-985 may be modulating filamentation, which 
may manifest in different metabolic rates. To investigate this observation further, 2 mutants 
(that had >100% metabolic rate) from GRACETM plate 2 were chosen to be validated with 
neutrophils (along with the 23 susceptible mutants).  
 
After the initial validation with neutrophils, 11 out of 25 mutants were more susceptible to 
neutrophils than the WT control. Interestingly, the two previously chosen “resistant” mutants 
from GRACETM plate 2 showed similar susceptibility to neutrophils to the WT control. This 
evidence coupled with an unusually high number of mutants with >100% metabolic rate 
suggested that the resulting mutants with over 100% metabolic rate were likely to have been 
due to experimental artefacts. However, this statement is not entirely conclusive as only 2 
mutants (out of >100 mutants) were validated with neutrophils. Due to large scale screening, 
it was expected to have some false-positive results. Thus, the two chosen mutants might have 
been those false positives. Not validating all previously identified resistant mutants made it 
impossible to state if the results were purely due to experimental artefacts. It also means that I 
might have missed mutants that are, in fact, resistant to neutrophils. In addition, neutrophils 
were slightly more potent at killing C. albicans compared to PLB-985 cells (Chapter 3), and 
this could perhaps explain the changes in C. albicans survival rate.   
 
After three additional validations with neutrophils, 5 mutants (Table 4.2) with the following 
repressed genes were found to be susceptible to neutrophils: BRR2, TAF7, NOC3, TFB3, SMT3 
with approximately 38%, 44%, 27%, 28% and 29% reduction in cell viability relative to the 
CaSS1 control, respectively. Therefore, this suggested that these genes may play important 
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roles in C. albicans anti-neutrophil antifungal responses. Most of the identified genes’ 
functions are still not well characterised and how these mutants interact with neutrophils is 
unknown. The next step was to study these 5 mutants’ interactions with neutrophils and 
characterise their functions. Out of these five mutants, noc3 was the only mutant that was 
borderline significant in the killing assay (p<0.053). Even though it was statistically near 
significance, it may have an important biological function. Therefore, I chose to investigate its 
function further with the other 4 mutants.  
 
The growth curves revealed that all mutants, except the noc3 mutant, exhibited similar trends 
to the WT control with a relatively similar growth rate and max growth. This suggested that 
their growth rates did not affect their susceptibility to neutrophils. However, the noc3 mutant 
appeared to have a delay in growth with a slower growth rate than the WT control. This is 
consistent with previous literature where poor growth was observed in NOC3 deficient S. 
cerevisiae compared to its WT control (Milkereit et al., 2001, Zhang et al., 2002). NOC3 has 
also been described as an essential gene for cell growth (Milkereit et al., 2001). This implied 
that the noc3 mutant growth defect could affect its susceptibility to neutrophils. Nevertheless, 
the noc3 mutant growth defect may not be the sole factor for its susceptibility to neutrophils as 
each mutant was individually diluted to the MOI of 5 before co-incubating with neutrophils. 
Thus, this would have taken poor growth into consideration. It is also important to consider 
that these mutants were grown in YPD media at 30oC (see section 2.2.2.4). This is a different 
condition to the killing assay, where mutants were grown in RPMI-1640 at 37oC in a static 
incubator while encountering neutrophils. Therefore, the growth curves may not be a true 
reflection of how the mutants were growing. So, if I were to do the experiment again, I would 
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Despite the novel discoveries, there were many limitations to my experiments that should be 
considered. One of the significant limitations was not being able to add the same cell number 
of mutants across the 96-well plate. Due to a high number of mutants per plate, diluting each 
mutant to the exact MOI of 5 when doing the GRACETM library screen was not possible. Thus, 
the number of cells added to the wells was based on estimation (see section 2.2.2.2). Many 
factors can influence this estimation. For example, not all mutants had the same growth rates 
(Supplementary figure 2), meaning that more cells would have been added to the wells of 
mutants with a faster growth rate than those with a slower growth rate. Another influencing 
factor was the number of the cells that were initially inoculated in an overnight culture. This 
may not significantly affect fast-growing mutants’ cell numbers, but it certainly would affect 
the mutants with a slow growth rate. It is also important to point out that I did not consider the 
morphology state of the mutants when doing the MOI estimation because it was impossible to 
do so. This means that I might have underestimated the number of mutants locked in a hyphal 
phase as they would not have been well suspended in solution and tend to clump together. A 
study suggested that using dry mass (correlated to cell surface area) instead of MOI number 
might be a better method to study the interactions between C. albicans and neutrophils as it 
accounted for cells with growth defects (i.e., cells that locked in either yeast or hyphal phase) 
(Hosseinzadeh and Urban, 2013). Also, there are many other ways C. albicans interacts with 
or responds to neutrophils (as mentioned in Chapter 1) that are driven by intracellular 
signalling, which is mainly influenced by cell number and not necessarily by the cell surface 
area. Therefore, using the MOI number might be the most appropriate method to study the 
interaction between C. albicans and neutrophils.  
 
The MOI number is a crucial factor that influences the susceptibility of C. albicans to PLB-
985 or neutrophils, as shown in chapter 3. This means that some mutants may have been 
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susceptible to PLB-985 purely because of having a lower MOI number. The opposite reasoning 
could also be applied to some resistant mutants. This may help to explain why over 50% of all 
mutants screened were shown to be resistant to PLB-985. Similarly, because too many cells 
were added to the wells, overpopulation may cause resorufin to reversibly reduce to the non-
fluorescent dihydroresorufin (çakır and Arslan, 2010, Chen et al., 2015), as explained in 
chapter 3 (see section 3.4). This is likely to be the case with non-PLB-985 treated wells, as no 
cells were killed. Therefore, overpopulation is likely to have occurred, especially when many 
cells were added in the beginning. This could explain why so many mutants (over 36% of all 
mutants screened) had >100% metabolic rate.  
 
Due to time constraints, I failed to thoroughly validate all 23 mutants that had been identified 
from the GRACETM library screen with neutrophils. For example, an initial screen with 
neutrophils from one donor was not an ideal decision as this does not consider neutrophil 
genetic variations between different donors or differences in neutrophil subpopulations (Abbas 
et al., 2018, Naranbhai et al., 2015, Ng et al., 2019, Nibali et al., 2010, Treffers et al., 2018). 
For example, if a “healthy” donor had recently experienced an infection or suffered from 
inflammatory conditions, they may have had a greater immature neutrophil population in their 
circulation (Carissimo et al., 2020, Carmona-Rivera and Kaplan, 2013, Mortaz et al., 2018, 
Seebach et al., 1997, Silvestre-Roig et al., 2019). Therefore, the isolated neutrophils may not 
have been efficient at killing C. albicans. It is possible that some “healthy” donors may have 
been infected with COVID-19 but were asymptomatic, which could also affect the ratio of 
neutrophil subsets (Carissimo et al., 2020). The variation in neutrophil responses against C. 
albicans can be seen in the neutrophil optimisation data (Figure 3.4) in chapter 3 and 
GRACETM mutant validation data (Figure 4.8). Therefore, there is a need to repeat the 
validation experiment several times with different donors to have more representative and 
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meaningful results. Also, the Welch unpaired t-test used in Figure 4.8 may not be the most 
powerful choice of statistical testing as it could introduce type 1 error. A more powerful choice 
of test would be one-way ANOVA. However, the WT and mutants did not have the same 
variance despite them being normally distributed. Therefore, the Welch unpaired t-test was the 
most suitable choice for statistical testing. Perhaps, having a larger sample size (i.e., more 
biological repeats) would allow more powerful statistical testing to be performed.  
 
One major downfall of the screen was that it failed to identify mutants that were resistant to 
neutrophils (i.e., mutants lacking genes that caused them to be more vulnerable to neutrophil 
killing) despite over 50% of all mutants screened having greater metabolic activity than WT. 
It is likely that most of these mutants were false positives. This could also indicate that the 
optimised killing assay method was not sensitive enough to detect resistant mutants. If I have 
more time, I would optimise my killing assay by experimenting with different MOI numbers 
(i.e., between MOI of 1 and 5) and different alamarBlueTM incubation periods to better detect 
both directional changes. Also, it is important to continue to screen the rest of the GRACETM 
library to reveal novel genes that may be important in anti-neutrophil antifungal responses.  
 
Finally, my killing assay does not measure actual killing of C. albicans as the alamarBlueTM 
fluorescence signal is correlated to cell metabolic activity, which can be influenced by many 
factors (as mentioned above). This means that it does not tell us how many C. albicans cells 
survived after being challenged with PLB-985 or neutrophils. If time were not a limiting factor, 
I would further validate the five mutants with a more sensitive and specific assay, such as the 
colony-forming unit (CFU)-based killing assay. Nevertheless, the alamarBlueTM-based killing 
assay is an excellent method for large-scale screening, like the GRACETM library, where it is 
impossible to perform a CFU-based killing assay.  
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4.4 CONCLUSION  
 
From the data presented in this chapter, I discovered five promising C. albicans mutants from 
the GRACETM library that were susceptible to primary human neutrophil killing. Therefore, 
their repressed genes may play a vital role in escaping from neutrophil antifungal responses. 
My next step was to characterise these mutants’ functions and their interactions with 
neutrophils.   
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CHAPTER 5: CHARACTERISING 
SUSCEPTIBLE GRACETM MUTANTS 
 
5.1 INTRODUCTION  
 
Like many pathogens, C. albicans may evolve and mutate to a more immune resistant strain 
that has the capability to employ novel mechanisms to overcome neutrophil antifungal 
responses, such as altering its stress response pathways, ROS neutralisation and morphology 
to avoid phagocytosis and NETosis (Barelle et al., 2006, Branzk et al., 2014, Ermert et al., 
2013, Martchenko et al., 2004, Miramon et al., 2012). By identifying these mutated genes or 
their functions, it could be possible to understand the anti-neutrophil antifungal response 
mechanisms and ultimately propose new therapeutic targets for C. albicans infections, such as 
candidemia. 
 
The research aim of this chapter was to characterise the five GRACETM mutants which have 
been previously shown to be susceptible to neutrophil killing (as summarised in Table 4.2).  
 
This chapter research objectives were to assess the mutants’:  
• Ability to form somatic hyphae 
• Susceptibility to hydrogen peroxide 
• Susceptibility to cell wall stressors 
• Ability to induce neutrophil reactive oxygen species  




5.2.1 GRACETM MUTANTS ARE PROFICIENT IN 
MORPHOLOGY SWITCHING 
 
To examine the GRACETM mutants’ ability to form somatic hyphae, cells were grown in YPD 
media with 10% FCS for 2 hours. The morphology index (MI) score, ranging from 0 to 5, was 
calculated to quantify the DIC images (see section 2.2.6). Cells with an MI score closer to 1 
are considered to be true yeast cells, while an MI score closer to 4 is considered to be true 
hyphal cells (Merson-Davies and Odds, 1989). I included a hyperfilamentous mutant, tup1D/D, 
as a positive control.  
 
All C. albicans strains appeared to have a rounded morphology with MI scores that were closer 
to a true yeast cell in the absence of FCS and at 30 oC, apart from the tup1D/D mutant, which 
had a more elongated morphology and the MI score closer to a true hyphal cell (Figure 5.1 and 
Table 5.1). Interestingly, some cells of the noc3 mutant seemed to have an elongated shape in 
the absence of FCS at 30 oC (Figure 5.1). Also, the MI score of the noc3 mutant appeared to 
be slightly closer to an MI score of a true hyphal cell compared to its WT control and other 
four GRACETM mutants in the absence of FCS at 30 oC (Table 5.1). When C. albicans were 
incubated with FCS at 37 oC, there were increases in the number of cells with elongated 
morphology with MI scores closer to the true hyphal cells, except from the tup1D/D mutant and 
noc3 mutant, where there were negligible changes in the MI scores (Table 5.1).  
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Overall, the DIC images and MI scores showed that, to a certain extent, all GRACETM mutants 
had the ability to switch on filamentous growth. However, four out of five mutants (brr2, noc3, 
tfb3, smt3) seemed to have slightly lower capability to switch on hyphal growth compared to 













entation induced by FC
S. D
IC im




utants and their W
T control and a positive 












 FCS for 2 hours at 
37 oC and 200 rpm
 (see section 2.2.6). D
IC im
ages w




icroscopy before and after FCS incubation. 
Representative im
ages of each m








Source Mutant Morphology Index (MI ± SD) 





WT  2.06 ± 0.32 3.59 ± 0.32 
brr2 2.15 ± 0.46 2.80 ± 0.77 
taf7 2.13 ± 0.24 3.23 ± 0.71 
noc3 2.56 ± 0.92 2.82 ± 0.85 
tfb3 2.09 ± 0.34 2.97 ± 0.71 
smt3 2.11 ± 0.34 2.78 ± 0.51 
Diezmann 
Archive 
SN95 1.93 ± 0.23 3.68 ± 0.83 
tup1Δ/Δ 3.80 ± 0.64 3.78 ± 0.61 
 
Table 5.1: GRACETM mutants can form somatic hyphae. After 4 hours of subculturing, C. 
albicans was grown in YPD media with 10% FCS for 2 hours at 37 oC and 200 rpm (see section 
2.2.6). Then, the morphology index (MI) score of each C. albicans was calculated based on 
DIC images. MI ± SD, n=1. MI score closer to 1 is considered true yeast cells, while MI closer 
to 4 is considered true hyphal cells.   
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5.2.2 THE GRACETM MUTANT SURVIVAL RATE POST-
EXPOSURE TO H2O2 
 
Hydrogen peroxide (H2O2) is one of the intermediate products of the neutrophil oxidative burst. 
C. albicans can reduce lethal ROS products such as superoxide into a less reactive H2O2, which 
in turn can be oxidised into a deadly hypochlorous acid (HOCL) by neutrophil’s MPO (Amulic 
et al., 2012, Jamieson et al., 1996, Kobayashi et al., 2002, Segal, 2005). Although H2O2 is less 
deadly than superoxide and HOCL, it is still toxic to the cells. Therefore, some C. albicans 
mutants may not be able to tolerate H2O2, making them susceptible to neutrophil killing. To 
examine the GRACETM mutants’ susceptibility to H2O2, cells were co-incubated with 0.1 mM 
H2O2 for 1 hour, and their survival rate was calculated based on CFU counts (see section 2.2.7).  
 
The Hog1 pathway plays a crucial role in C. albicans resistance to osmotic and oxidative 
stresses, and C. albicans lacking HOG1 was found to be susceptible to H2O2 (Alonso-Monge 
et al., 2003, Ernst and Pla, 2011, Haghnazari and Heyer, 2004). Therefore, I included the 
hog1D/D mutant as a negative control. The data showed that the negative control (64.11 ± 
4.90%) had a lower survival rate than its SN95 parental control (87.77 ± 6.99%) (Figure 5.2). 
However, this difference was not statistically significant. This suggested that the assay failed 
to work as the hog1D/D mutant was previously optimised to be highly susceptible to H2O2 
compared to the SN95 (data not shown, optimised by the Diezmann lab). Therefore, no definite 
conclusion could be drawn from this figure, which means there is a need to repeat the 
experiment.  
 
The H2O2 assay showed that three GRACETM mutants [taf7 (73.35 ± 11.12%), tfb3 (80.03 ± 
17.74%), smt3 (87.77 ± 6.99%) ] had a similar survival rate compared to the WT control (81.89 
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± 9.91%), while the other one had a lower survival rate [brr2 (58.57 ± 4.98%)] (Figure 5.2). 
The result of the noc3 mutant was excluded as no growth was detected in both H2O2 treated 
and untreated groups. Also, the survival difference between the brr2 mutant and its WT control 
was not statically significant. This suggested that all GRACE mutants had the same 
susceptibility to H2O2 as the WT control.  
 
 
Figure 5.2: The GRACETM mutant survival rate post-exposure to H2O2. C. albicans - H2O2 
stress assay was performed, and the survival rate (%) was calculated based on CFU counts (see 



































5.2.3 GRACETM MUTANTS ARE SUSCEPTIBLE TO CELL 
WALL STRESSORS   
 
To assess cell wall integrity, C. albicans were spotted onto YPD agar plates containing either 
CFW or Congo Red reagents and incubated at 37 oC for 2 days (see section 2.2.8). CFW and 
Congo Red interfere with the assembly of the fungal cell wall and thus weaken the cell wall by 
targeting chitin and inhibiting enzymes responsible for the binding of chitin to b-glucans (Ram 
and Klis, 2006, Roncero and Durán, 1985). Mutants with low cell wall integrity and those with 
defective cell wall stress responses are expected to be susceptible to CFW and Congo Red 
reagents.  
 
Protein kinase C (PKC) and MAPK pathways are involved in C. albicans cell wall integrity 
and biogenesis (Csank et al., 1998, Ernst and Pla, 2011). C. albicans cells with defective PKC 
and MAPK pathways, such as those lacking EFG1, CPH1, MKK2, PKC1 were found to be 
susceptible, and those lacking HOG1 were found to be resistant to CR and CFW (Eisman et 
al., 2006, Haghnazari and Heyer, 2004, Navarro-García et al., 2005, Román et al., 2015). 
Therefore, the following controls were included: negative controls (efg1Δ/Δ cph1Δ/Δ, mkk2D/D 
and pkc1Δ/D) and a positive control (hog1Δ/D).  
 
The images revealed that two negative controls (mkk2D/D and pkc1Δ/D) had poor growth 
compared to their SN95 parental control on both CFW and Congo Red (Figure 5.3). The images 
also illustrated that the positive control had slightly better growth on the CFW plate and 
unexpectedly slightly poorer growth on the Congo Red plate. Therefore, only limited 
conclusions could be drawn from this experiment.  
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All C. albicans strains that grew on both CFW and Congo Red plates exhibited lower levels of 
growth than on the YPD only plate (Figure 5.3). This suggested that all C. albicans strains 
were somewhat susceptible to CFW and Congo Red. The images also revealed that two out of 
five mutants (brr2 and smt3) seemed to have poorer growth on the CFW and Congo Red agar 
plates than their WT control. Meanwhile, the taf7 mutant seemed to grow slightly better than 
its WT control on both CFW and Congo Red agar plates. Interestingly, the tfb3 mutant seemed 
to grow slightly better on the CFW plate and poorer on the Congo Red plate than its WT 
control.  
 
The data for noc3, CAI4 and efg1Δ/Δ cph1Δ/Δ strains were excluded. This is because the noc3 
mutant did not grow robustly on the YPD only plate. Meanwhile, the efg1Δ/Δ cph1Δ/Δ mutant 
grew too well compared to its CAI4 parental control on the YPD only plate. Therefore, it was 
quite difficult to judge their susceptibility to Congo Red and CFW reagents by eye, and thus 
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5.2.4 GRACETM MUTANTS ARE STRONG INDUCERS OF 
NEUTROPHIL OXIDATIVE BURST 
 
Reactive oxygen species (ROS) production is one of the main neutrophil antifungal responses 
against C. albicans (Jamieson et al., 1996, Segal, 2005). The respiratory burst using the luminol 
method was performed to assess how the GRACETM mutants affect neutrophil ROS production 
(see section 2.2.9).  
 
I first compared the following C. albicans mutants from the Diezmann archive to analyse how 
filamentation ability affects the oxidative burst: a hyperfilamentous mutant (tup1Δ/Δ) and a 
yeast-locked mutant (efg1Δ/Δ cph1Δ/Δ). The kinetic curves showed that the efg1Δ/Δ cph1Δ/Δ 
mutant (14,384 ±4,603) had a considerably higher overall ROS chemiluminescence signal than 
its CAI4 parental strain (5,646 ± 2,816) (Figure 5.4a). Interestingly, the tup1Δ/Δ mutant (1,039 
± 177) had a much lower overall ROS chemiluminescence signal than its SN95 parental control 
(6,842 ± 3,064) (Figure 5.4a). However, it was difficult to quantify the tup1Δ/Δ mutant, and 
thus I may have added fewer cells than expected.  
 
The area under the ROS curves was calculated to estimate neutrophil total ROS production 
(Figure 5.5). The graph also showed that the total ROS production triggered by the efg1Δ/Δ 
cph1Δ/Δ mutant (775,361 ± 211,039) was significantly higher than the CAI4 control (313,737 
± 153,480). Although there was a visible difference in the total ROS production between the 
tup1Δ/Δ mutant (79,387 ± 17,093) and the SN95 control (501,207 ± 90,363), this difference 
was not statically significant. Therefore, the data suggested that the yeast-lock mutant may be 
a potent ROS inducer, while the hyperfilamentous mutant may be a weak ROS inducer.  
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The kinetic curves showed that out of five GRACETM mutants, tfb3 had the highest, and smt3 
had the lowest overall ROS chemiluminescence signal (Figure 5.4b). Three GRACETM mutants 
[brr2 (9,152 ± 405), taf7 (8,660 ± 360), tfb3 (9,859 ± 896)] appeared to have a similar overall 
ROS chemiluminescence signal based on the peak values to their WT control (8,705 ± 1,239), 
while the other two mutants [noc3 (6,367 ± 177) and smt3 (5,375 ± 803)] had a far lower overall 
ROS chemiluminescence signal than the WT control (Figure 5.4b). It also appeared that the 
taf7 mutant peaked relatively early (at 16 minutes) compared to the other mutants, which 
peaked at a similar time to the WT (at ~24 minutes).  
 
Like the GRACETM mutant kinetic curves, tfb3 triggered the highest total ROS production, 
while smt3 elicited the least total ROS production. In contrast to the kinetic curves, all 
GRACETM mutants [brr2 (458,388 ± 41,548), taf7 (417,7752 ± 19,761), noc3 (334,216 ± 
4,941), tfb3 (524,553 ± 72,462), and smt3 (315,016 ± 58,575)] induced a similar amount of 
ROS production to their WT control (433,254 ± 88,321) (Figure 5.5).  
 
Overall, the respiratory burst data suggested that the five GRACETM mutants had a similar 








Figure 5.4: Neutrophil ROS production in response to C. albicans infection. (a.) 
Chemiluminescence of reactive oxygen species (ROS) with C. albicans mutants from the 
Diezmann archive. (b.) Chemiluminescence of ROS with GRACETM mutants and their WT 
control. Chemiluminescence (mean in RFU) ± SEM. n=3 donors. Neutrophils were challenged 
with C. albicans at an MOI of 5 (see section 2.2.9).  


























































Figure 5.5: Neutrophil total ROS production in response to C. albicans infection. 
Neutrophils were challenged with C. albicans at an MOI of 5, and the area under the ROS 
curve of each C. albicans strain was calculated to determine total ROS production (see section 
2.2.9). Area under the curve (mean) ± SEM. Statistical significance was calculated by one-way 




























































5.2.5 MUTANTS WITH GROWTH DEFECTS TRIGGERED LESS 
NETOSIS 
 
To examine the GRACETM mutants’ ability to induce NETosis, a simple NETs assay was 
performed using fluorescent DNA staining dyes: SytoxTM Orange (detects extracellular DNA, 
which is assumed to indicate NETs) and SytoTM Green (detects intracellular DNA). NET 
images were then taken by the EVOS FL Cell Imaging System (see section 2.2.10). Then, the 
number of NETs (red areas in Figure 5.6-5.7) per image was quantified.   
 
I included neutrophils only condition as a negative control, where no NETs were detected 
(Figure 5.6, top row). To assess how filamentation ability affects NETosis, tup1Δ/Δ and 
efg1Δ/Δ cph1Δ/Δ mutants were included in the NETs assay. Based on NETs per image (NPI) 
data, the efg1Δ/Δ cph1Δ/Δ mutant (195 ± 12) had a significantly lower NPI than its CAI4 
parental control (433 ± 20) (Figure 5.8). Unexpectedly, the tup1Δ/Δ mutant (123 ± 17) appeared 
to have a significantly lower NPI than its SN95 parental control (367 ± 57). This is likely 
because fewer cells of the tup1Δ/Δ mutant were added due to the quantification difficulty. 
 
Figure 5.6-5.7 (top row) shows that all C. albicans, including the five GRACETM mutants, were 
capable of inducing NETs release. Interestingly, the images show that all GRACETM mutants 
exhibited filamentous growth after 4 hours of incubation in RPMI-1640 (with 2% human 
pooled plasma). However, four out of five GRACETM mutants (brr2, noc3, tfb3 and smt3) 
appeared to be unable to form true hyphae compared to the WT control as some of their cells 




Out of five GRACETM mutants, tfb3 (379 ± 13) and smt3 (379 ± 22) triggered the most, and 
noc3 (107 ± 15) triggered the least NETs release, while the other two mutants [brr2 (303 + 23) 
and taf7 (285 ± 55)] induced similar NETs release levels to their WT control (286 ± 21) (Figure 
5.8). However, the differences between tfb3 and smt3 to their WT control were not statistically 
significant despite visible changes in NPI. Nonetheless, there was a statistically significant 
difference between noc3 and its WT control.  
 
Overall, my data suggested that mutants with growth defects (i.e., either in yeast-locked or 
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Figure 5.8: GRACETM mutants can trigger NETosis. Neutrophils were challenged with C. 
albicans at an MOI of 5, and the number of NETs per image of each C. albicans strain was 
calculated (see section 2.2.10). NETs per image (mean) ± SEM. Statistical significance was 

















































This chapter aimed to characterise the five GRACETM mutants, (as summarised in Table 4.2) 
functions and their interactions with neutrophils.  
 
The ability to switch between the yeast and the hyphal phase is one of the main virulence 
factors of C. albicans (Pappas et al., 2018, Wibawa, 2016). Mutants that lack this ability are 
more likely to be susceptible to neutrophil killing (Ermert et al., 2013, Jayatilake et al., 2007, 
Moyes et al., 2010, Naglik et al., 2011, Salvatori et al., 2018). To assess the morphogenetic 
diversity of the GRACETM mutants, a serum-induced filamentation assay was performed. The 
assay revealed that all GRACETM mutants could form somatic hyphae to a certain extent in 
response to FCS serum. Three GRACETM mutants (brr2, tfb3, smt3) appeared to be slightly 
less efficient at transitioning from yeast to hyphae than the WT control. Therefore, these three 
genes may be involved in cell morphogenesis.  
 
The SMT3 gene encodes a ubiquitin-like protein (SUMO), which modulates post-translational 
modification of many proteins (Dieckhoff et al., 2004, Ghaemmaghami et al., 2003, Johnson 
et al., 1997, Martin and Konopka, 2004, Skrzypek et al., 2017, Takahashi et al., 1999). A study 
showed that the smt3 mutant could elongate its cell in response to FCS serum induction but 
failed to form a true hypha (Leach et al., 2011). This evidence is consistent with the MI score 
of the smt3 mutant reported in this project. Perhaps, SUMO modifies proteins that are involved 
in the yeast-hypha morphogenesis.  
 
The BRR2 gene encodes pre-mRNA-splicing helicase, which plays an essential role in pre-
mRNA splicing (Ghaemmaghami et al., 2003, Hahn et al., 2012, Maeder et al., 2009, Pena et 
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al., 2009, Skrzypek et al., 2017, Zhang et al., 2009). The TFB3 gene encodes RNA polymerase 
II transcription factor subunit 3, which is vital for DNA transcription and repair (Faye et al., 
1997, Feaver et al., 1997, Ghaemmaghami et al., 2003, Skrzypek et al., 2017). Therefore, it 
may be possible that the BRR2 and TFB3 genes products are involved in the transcription of 
other important genes in yeast-hypha morphogenesis.  
 
Both before and after serum treatments, the noc3 mutant interestingly appeared to have MI 
scores that are indicative of hyphal growth. This suggested that the noc3 mutant may not have 
the ability to entirely switch between yeast and hyphal forms and thus implied that the NOC3 
gene may play an essential role in the yeast-hypha morphogenesis. Two studies showed that 
NOC3 is an essential gene for the initiation of DNA replication and the synthesis of 60S 
ribosomal subunits in S. cerevisiae (Milkereit et al., 2001, Zhang et al., 2002). Since these two 
processes are important for cell maturation, the studies suggested the NOC3 gene to be vital 
for fungal growth (Milkereit et al., 2001, Zhang et al., 2002). This suggestion is further 
supported by my growth curve data (Chapter 4, Figure 4.9), where the noc3 mutant had the 
lowest growth rate and maximum growth compared to its WT and other tested GRACETM 
mutants. Perhaps, the inability to transition between the two morphologies and the growth 
defect caused the noc3 mutant to become susceptible to neutrophil killing. 
 
Despite the interesting findings, it is important to consider that the serum-induced filamentation 
assay was done in completely different conditions to the killing assay. For example, YPD 
media was used instead of RPMI-1640 media, and 10% FCS was used instead of 2% human 
pooled plasma serum. These conditions may have some influence on C. albicans behaviour. 
Maybe to have a more informative and reflective result of how C. albicans dimorphism affects 
neutrophil killing ability, the filamentation assay should be conducted in similar conditions to 
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the killing assay. Also, C. albicans mutants were only incubated with FCS for 2 hours. This 
means that the obtained data might not truly reflect their ability to form somatic hyphae as 
some of them may take longer to switch on the filamentous growth programming. Furthermore, 
I only performed the serum-induced filamentation assay once. Thus, more experimental repeats 
are needed to produce a more representative result. In addition, C. albicans strains, such as the 
efg1Δ/Δ cph1Δ/Δ mutant, should be included in the assay as a negative control.  
 
The H2O2 assay was performed to assess the GRACETM mutants’ ability to tolerate a neutrophil 
toxic intermediate product, H2O2 (Amulic et al., 2012, Jamieson et al., 1996, Kobayashi et al., 
2002, Segal, 2005). The assay failed to work as there was no significant difference between 
the survival rate of the negative control and the WT. Despite this, there seemed to be some 
interesting trends among the GRACETM mutants. For example, brr2 and tfb3 mutants had a 
consistently lower survival rate than their WT control (Supplementary figure 3). This may 
suggest that BRR2 and TFB3 genes might have some contribution to H2O2 tolerance. However, 
no valid conclusions can be drawn from this experiment until repeated. The use of old H2O2 
stock (from 2016) is likely to explain why the experiment did not work. Since H2O2 is 
inherently unstable, it is likely that I have used a lower concentration of H2O2 than the one 
stated in the method. If I were to do the experiment again, I would make sure to use the correct 
concentration of H2O2. I would also adjust the plating cell concentration for slow grower 
mutants like the noc3 mutant, where no growth was detected in both H2O2 treated and untreated 
groups.  
 
CFW and Congo Red interfere with cell wall formation by inhibiting chitin and b-(1,3)-glucan 
synthases (Ram and Klis, 2006, Roncero and Durán, 1985). Thus, these reagents were used to 
test the cell wall integrity of each GRACETM mutant. Compared to their WT control, brr2 and 
 114 
smt3 mutants appeared to be more susceptible, and taf7 mutant seemed to be more resistant to 
Congo Red and CFW reagents. This suggested that BRR2, SMT3 and TAF7 genes might play 
essential functions in maintaining cell wall integrity, such as synthesising chitins and b-
glucans.  
 
A study also showed that the smt3 mutant grew poorly in Congo Red and CFW compared to 
its control, which further reinforced the potentially critical role of the SMT3 gene in cell wall 
damage signalling (Leach et al., 2011). The study also showed Erg13 protein to be one of the 
SUMOylating targets in C. albicans. Erg13 is a protein involved in ergosterol biosynthesis, a 
crucial process in maintaining the cell membrane (Leach et al., 2011, Lv et al., 2016, Servouse 
et al., 1984). Perhaps, cells lacking the SMT3 gene might have a defect in the cell membrane 
and cell wall structures, thus making them more susceptible to Congo Red and CFW.  
 
The TAF7 gene encodes a transcription initiation factor TFIID subunit 7 protein, which is 
involved in the regulation of gene expression by RNA polymerase II (Bhattacharya et al., 2014, 
Kolesnikova et al., 2018, Matangkasombut et al., 2000, Sanders et al., 2002, Sanders and Weil, 
2000). Although no studies were done on how TAF7 affects cell wall synthesis, my data suggest 
that the TAF7 gene may be involved in the breakdown of cell wall components as the mutant 
lacking TAF7 was more resistant to CFW and Congo Red. For example, TAF7 may enhance 
the transcription of genes that encode cellulase and proteases.   
 
Interestingly, the cell wall stressors assay also showed that the tfb3 mutant was more resistant 
to CFW and more susceptible to Congo Red than the WT control. As CFW and Congo Red 
interfere with the C. albicans cell wall in a similar way, it was expected that the tfb3 mutant 
would have a similar susceptibility pattern to both reagents. One explanation for this difference 
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could be that CFW may prefer to bind to chitin than b-glucans, while Congo Red may prefer 
to bind to b-glucans than chitin. Therefore, if a mutant, such as tfb3, has more chitin and fewer 
b-glucans expressed on its cell wall, it might be less susceptible to CFW and more susceptible 
to Congo Red. A study showed that the TFB3 gene was upregulated in C. albicans treated with 
caspofungin, a drug that works similarly to CFW and Congo Red by inhibiting b-1,3-glucan 
synthases (Reinoso-Martin et al., 2003). This suggested that TFB3 may be important in the 
synthesis of b-1,3-glucan. For example, it perhaps enhances the transcription of b-1,3-glucan 
or enzymes that are involved in b-1,3-glucan synthesis. Also, this piece of evidence has 
somewhat supported the response of the tfb3 mutant to Congo Red as cells lacking the TFB3 
gene would be expected to be more susceptible to cell wall stressors.  
 
Before any definite conclusions can be made, it is important to consider some limitations of 
the cell wall stressor assay. Firstly, the results were not quantitative, and any analyses were 
done qualitatively by eye. This means that different individuals may interpret the data 
differently. Using the CFU-based method (similar to the H2O2 stress assay as described in 
section 2.2.7) may be a better way to conduct this experiment to avoid bias. Also, the assay 
does not take the growth rate of C. albicans into account. Therefore, it is difficult to distinguish 
between the cell wall susceptibility and the mutant’s ability to grow. For example, faster growth 
mutants may look less, and slower growth mutants may look more susceptible to CFW and 
Congo Red than they actually are. Furthermore, the assay was conducted once, and thus more 
repeats are needed to confirm the finding.  
 
ROS production is one of the main neutrophil antifungal responses when encountering C. 
albicans (Jamieson et al., 1996, Segal, 2005). The ROS kinetic curves showed that all mutants 
could induce ROS production. noc3 and smt3 mutants appeared to be weak ROS inducers as 
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they had the lowest ROS peaks compared to their WT and other mutants. However, the area 
under the kinetic curves revealed no significant difference in the total ROS production between 
GRACETM mutants and their WT. Interestingly, the total ROS production triggered by smt3 
appeared to be consistently lower than the total ROS production induced by the WT across 
each biological replicate (i.e., across different neutrophil donors), suggesting it to be a weak 
ROS inducer (Supplementary figure 4). Conversely, the total ROS production triggered by the 
tfb3 mutant appeared to be consistently higher than the total ROS production induced by the 
WT across each biological replicate, suggesting it to be a potent ROS inducer (Supplementary 
figure 4).  
 
It became apparent that interpreting the ROS kinetic curves and the area under the kinetic 
curves can lead to contradicting conclusions, such as how powerful each mutant is at inducing 
ROS production. This raises the question of how to define a “strong inducer”. Is it by how 
much ROS is produced at a specific time (i.e., the peak) or how much ROS is produced over 
time (i.e., the area under the curve)? ROS production initiation relies on the recognition of 
pathogens (Nguyen et al., 2017). Therefore, mutants that induced less ROS production, such 
as noc3 and smt3 mutants, may have fewer PAMPs on their surface, making them harder to 
recognise. The opposite could be applied to mutants that induced more ROS production, such 
as the tfb3 mutant. This further suggested that NOC3, SMT3 and TFB3 genes may be involved 
in the synthesis of PAMPs that are responsible for ROS induction. Furthermore, previous 
research suggested that there may be a positive correlation between ROS production and 
mutants (such as sod5Δ/Δ) that are sensitive to oxidative stress (Martchenko et al., 2004, 
Miramon et al., 2012). This is somewhat similar to the finding of the tfb3 mutant, where it 
consistently induced a higher ROS production and had a consistently lower survival when 
being challenged with H2O2 than its WT control. This further suggested that the TFB3 gene 
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may also be important in the detoxification of ROS. For example, Tfb3 possibly enhances the 
transcription of proteins that can neutralise ROS, such as Sods. It is worth mentioning that the 
ROS assay does not tell us about how susceptible the C. albicans strains are to ROS. For 
example, mutants that induce more ROS are not necessarily more susceptible than those that 
induce less ROS. Such conclusions can only be made from a survival assay that exposes C. 
albicans directly to ROS components, such as superoxide and H2O2.  
 
To assess how different morphologies could affect ROS production, I also stimulated 
neutrophils with the efg1Δ/Δ cph1Δ/Δ double mutant and the tup1Δ/Δ mutant. The data revealed 
that the tup1Δ/Δ mutant induced the least amount of ROS compared to other tested strains. This 
finding contradicts a ROS study, where the dry mass of C. albicans was used to stimulate 
neutrophils (Hosseinzadeh and Urban, 2013). The study showed that tup1Δ produced a similar 
level of ROS production to its WT and efg1Δ of the same mass (Hosseinzadeh and Urban, 
2013). As mentioned in chapter 4, hyperfilamentous mutants tend to clump together and are 
not well suspended, and thus I might not have added enough tup1Δ/Δ cells to trigger a robust 
ROS response. Perhaps using dry mass that accounted for cell surface area for this experiment 
might be more sensible as ROS initiation mainly relies on cell surface recognition. 
Furthermore, my data revealed that the efg1Δ/Δ cph1Δ/Δ mutant induced a significantly higher 
ROS production than its WT. This finding somewhat contradicts a macrophage study, where 
efg1Δ/Δ induced less ROS production, while efg1Δ induced more ROS production than its WT 
control (Zavrel et al., 2012). Conversely, the dry mass study showed that ROS induction by the 
efg1Δ mutant was overall slightly lower than its WT control (Hosseinzadeh and Urban, 2013). 
As three different yeast-locked mutants triggered different ROS responses and a yeast-locked 
mutant can trigger ROS as efficiently as a hyphae-locked mutant, it seems that the morphology 
of C. albicans is not a sole factor and may not play a significant role in ROS production. It is 
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also clear that more investigations are needed to clarify why different mutants of the same 
morphology-lock trigger ROS production differently. Furthermore, a separate assay for 
intracellular and extracellular ROS production should be conducted in the future as they may 
give more specific information on how each mutant affects neutrophil ROS production.  
 
NETosis is another important pathogen killing mechanism of neutrophils (Amulic and 
Sollberger, 2019, Branzk et al., 2014, Papayannopoulos, 2018). This mechanism is especially 
crucial in fighting against pathogens that are too large to be phagocytosed, such as C. albicans 
hyphae (Branzk et al., 2014, Pappas et al., 2018). To assess how each GRACETM mutant 
affected the release of NETs, the NETosis assay was performed. The data revealed that all C. 
albicans mutants could induce NETosis, which is consistent with previous observations 
(Branzk et al., 2014, Urban and Nett, 2019, Urban et al., 2006). However, out of all the 
GRACETM mutants, noc3 appeared to induce significantly fewer NETs than its WT. This result 
is similar to the efg1Δ/Δ cph1Δ/Δ mutant, which induced significantly fewer NETs than its 
parental control. The fluorescence images also showed that the noc3 mutant had a morphology 
closer to the efg1Δ/Δ cph1Δ/Δ mutant than the tup1Δ/Δ mutant. This evidence, together with 
its MI score (Table 5.1) and growth rate (Table 4.2), further indicated that the noc3 mutant has 
a growth defect and cannot form complete or true hyphae, which emphasises the importance 
of the NOC3 gene in morphogenesis. Furthermore, the finding is consistent with a previous 
study where the authors showed that larger pathogens (such as hyphal units of C. albicans and 
Aspergillus fumigatus) induced more NETosis than smaller pathogens (such as yeast units of 
C. albicans and small conidia) (Branzk et al., 2014). My evidence and previous findings 
suggest that NETosis may be selectively triggered depending on the size of the pathogen. 
Therefore, the morphology defect of the noc3 and efg1Δ/Δ cph1Δ/Δ mutants could explain why 
they stimulated fewer NETs. Furthermore, it has been shown that phagocytosis can inhibit 
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NETosis by downregulating neutrophil elastase (NE) translocation to the nucleus (Branzk et 
al., 2014). Perhaps, noc3 and efg1Δ/Δ cph1Δ/Δ mutants were cleared by phagocytosis due to 
their smaller size, and thus fewer NETs were released. In contrast to previous findings, the 
assay revealed that NETosis triggered by the tup1Δ/Δ mutant was significantly lower than its 
WT control, although this may be because fewer cells of these mutants were added due to 
difficulties in the calculation of cell numbers. Also, the tup1Δ/Δ mutant seemed to have a 
similar ability to induce NETosis to the noc3 and efg1Δ/Δ cph1Δ/Δ mutants. This disagreement 
is likely because I might not have added enough tup1Δ/Δ cells as previously explained.  
 
The NETosis assay also revealed an interesting trend for two GRACETM mutants (smt3 and 
tfb3), where they consistently induced higher NET release than their WT control 
(Supplementary figure 5). In addition, it appeared that these mutants could form hyphae but 
less extensive compared to their WT, as shown by the fluorescence images and previous MI 
scores. This suggested that C. albicans size may not be the only determining factor of NETosis. 
Perhaps, NETosis induction may depend on how much “NET-specific” PAMPs are presented 
on the cell wall rather than the actual size of the fungus. For example, the recognition of fungus 
by dectin-2 has been shown to be the main NETosis driver (Miura et al., 2019, 
Papayannopoulos, 2018, Wu et al., 2019). Therefore, a strong NETosis inducer mutant (such 
as smt3 and tfb3 mutants) may have a greater abundance of dectin-2 agonists, such as a-mannan 
(Gazendam et al., 2016, Gow et al., 2012). Furthermore, Candida biofilm studies showed that 
biofilm formation and its extracellular matrix could alter neutrophil recognition and impair 
NET formation (Johnson et al., 2016, Johnson et al., 2017). Mutants lacking SMT3 and TFB3 
genes may be defective at producing extracellular matrix and forming a biofilm. This could 
explain the NETosis trend of these mutants and their susceptibility to neutrophils.  
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There are some limitations to the NETosis assay that should be taken into consideration when 
making conclusions. For example, the SytoxTM Orange dye is not specific to NETs as it stained 
all extracellular DNA. This means that neutrophils that die by C. albicans-induced apoptosis 
will also be detected. Therefore, it is essential to validate this experiment with a more sensitive 
method, such as fluorescence staining of NET markers: NE translocation and citrullinated 
histone H3 (Amulic and Sollberger, 2019, Branzk et al., 2014). As C. albicans also had a 
similar SytoTM Green to live neutrophils (those with intact cell membrane), it was impossible 
to calculate a percentage of NETs, which is a more accurate quantification measure than NPI. 
To account for the variation of neutrophil responses due to genetic and environmental factors 






In this chapter, I have discovered novel characteristics of the five GRACETM mutants 
(previously identified in Chapter 4). My project revealed that a mutant lacking the BRR2 gene 
had an impaired ability to switch between yeast and hyphae and may be susceptible to H2O2 
oxidative stress. It also revealed that the fungal cell wall integrity was compromised in the brr2 
mutant. Conversely, the cell wall integrity seemed to be enhanced in a mutant lacking the TAF7 
gene. My study further showed that a mutant lacking the NOC3 gene appeared to have growth 
defects and could not undergo yeast-hyphae morphogenesis. The noc3 mutant also seemed to 
be a weak inducer of ROS and NET production. Conversely, a mutant lacking the TFB3 gene 
appeared to be a strong NET and ROS inducer. Like the brr2 mutant, my study suggested that 
the tfb3 mutant might have an impaired ability to transition between yeast and hyphae and may 
be susceptible to H2O2 oxidative stress. Similarly, a mutant lacking the SMT3 gene may also 
have an impaired ability to shift between the two morphologies. In addition, the cell wall 
integrity of the smt3 mutant appeared to be compromised and that the mutant seemed to be a 
weak ROS and a strong NET inducer.  
 
Finally, it is apparent that these five identified genes are crucial for C. albicans functions, such 
as undergoing yeast-hyphae morphogenesis and overcoming neutrophil antifungal responses 
(Figure 5.9). Therefore, more studies are required to investigate these genetic pathways, which 





Figure 5.9: A schematic diagram of a potential mechanism for the five identified genes.  
These mechanisms are drawn based on my findings together with previous evidence, as 
discussed in chapter 5. More studies are needed to investigate the proposed genetic functions 
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Supplementary figure 3: The GRACETM mutants may be susceptible to H2O2. C. albicans 
- H2O2 stress assay was performed, and the survival rate (%) was calculated based on CFU 











































Supplementary figure 4: Neutrophil ROS production in response to C. albicans infection. 
The graph shows the area under the ROS curve of the GRACETM mutants relative to WT. 













































Supplementary figure 5: NET production in response to C. albicans infection. The graph 
shows the number of NETs per image of the GRACETM mutants relative to WT. Statistical 
significance was calculated by one-way ANOVA; *p<0.05, n=3 donors. Neutrophils were 
challenged with C. albicans at an MOI of 5 (see section 2.2.10). 
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